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ABSTRACT

The dopamine transporter (DAT) is an integral membrane protein that mediates
the reuptake of synaptic dopamine and thus regulates the spatio-temporal dynamics of
dopaminergic neurotransmission. DAT is also the target of powerful addictive
psychostimulants, including cocaine and methamphetamine that resulted in dysregulation
of dopaminergic signaling. Complex control of DAT is exerted by various regulatory
processes, including posttranslational modifications. We previously found that DAT is
palmitoylated via the addition of a 16-carbon palmitic acid moiety to Cys 580.
Pharmacological and mutagenic studies determined that depalmitoylation conditions led
to reductions in Vmax and transporter levels, suggesting palmitoylation controls one or
more functions of DAT. Palmitoylation is a dynamic and reversible process catalyzed by
palmitoyl acyltransferases (PATs) and depalmitoylation is catalyzed by palmitoyl-protein
thioesterases (PPTs). PAT enzymes have been further classified as DHHC enzymes based
on a conserved cysteine rich domain and the active site sequence Asp-His-His-Cys.
Currently, 23 PAT enzymes have been identified in the human genome with some
associated with dopaminergic diseases such as schizophrenia; however, the enzymes that
act on DAT are unknown. Therefore, we hypothesized that specific PAT enzymes will
drive DAT palmitoylation, controlling expression, DA transport, and membrane lateral
mobility of the transporter. To address this question, we co-expressed a specific subset of

xiii

neuronally-expressed PATs individually with DAT and assessed DAT palmitoylation,
total and surface expression, transport activity, and lateral membrane mobility.
Additional studies were also conducted to investigate psychostimulant regulation of DAT
palmitoylation.
Palmitoylation assessed by acyl-biotin exchange revealed that the neuronal PATs,
DHHC2, DHHC3, DHHC8, DHHC15, and DHHC17 increased DAT palmitoylation at
Cys580, while several others had no effect, indicating a level of substrate specificity for
actions against DAT. We observed a correlation between increased DAT palmitoylation
and increased total DAT expression, consistent with a role for palmitoylation opposing
DAT degradation. DAT palmitoylation also led to enhanced DA uptake with no effect on
surface levels, suggesting that palmitoylation also increases transport capacity via an
alteration of DAT transport kinetics. Our results also indicated that DAT palmitoylation
increased the time for recovery after photobleaching, suggesting that increased
palmitoylation decreases the membrane lateral mobility of the transporter. Lastly, we
observed treatment with methamphetamine but not cocaine resulted in decreased DAT
palmitoylation in both heterologous cells and in animal models, suggesting that DAT
palmitoylation is regulated by psychostimulants. Palmitoylation thus plays an important
role in both short- and long-term regulation of DAT by controlling multiple functions.
Therefore, this modification could potentially affect neurotransmitter clearance in
dopaminergic disorders where palmitoylation may be impacted.
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CHAPTER I

INTRODUCTION
The Synaptic Neurotransmission of Dopamine

The brain is responsible for physiological and psychological processes of the
entire human body. It consists of billions of neurons which communicate by signals from
one neuron to another through the release of neurotransmitters. One particular
neurotransmitter we are interested in is dopamine (DA). DA was discovered in 1957, by
Dr. Arvid Carlsson, when he investigated dopamine in the brains of reserpinized animals
treated with L-DOPA (1). Initially, DA was thought to only be the precursor to another
neurotransmitter norepinephrine; however, Carlsson discovered that DA was important
for physiological function (1–3). DA is important for several physiological roles
including movement, reward, and mood. DA like other catecholamines (epinephrine and
norepinephrine) is derived from tyrosine which is abundantly found in dietary proteins.
Initially, tyrosine is transported into the dopaminergic neuron by amino acid transporters.
Once tyrosine enters the neuron, it is converted to L-3, 4-dihydroxyphenylalanine (LDOPA). This process is catalyzed by cytosolic tyrosine hydroxylase (TH) and the
cofactors oxygen, iron, and tetrahydrobiopterin hydroxylates tyrosine. This step in DA
synthesis is the rate-limiting step (4). L-DOPA is then decarboxylated to produce DA by
aromatic L-amino acid decarboxylase (AADC). Because DA is the starting compound to
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generate other neurotransmitters, DA synthesis regulates the synthesis of norepinephrine
and epinephrine, the other two catecholamines.
Once DA has been synthesized, the neurotransmitter is transported from the
cytoplasm into synaptic vesicles via the vesicular monoamine transporter 2 (VMAT2),
where it is stored until release. The concentration of DA in the vesicles is 0.1M, which is
10-1000 times higher than the level in the cytosol (4). Neurotransmitter release of DA is
initiated by an action potential that triggers the opening of voltage-gated Ca2+ channels
resulting in a rapid rise in intracellular Ca2+. The transient increase in Ca2+ stimulates the
fusion of the synaptic vesicles with the plasma membrane of the presynaptic neuron
(synaptic vesicular exocytosis) and the release of the stored DA into the synaptic cleft
(5). Once DA is released into the synaptic space it binds to specific receptors found on
both the pre and postsynaptic neurons. Neurotransmission is terminated when the excess
DA is removed from the synapses by diffusion or reuptake. A small amount of DA is
metabolized by catechol-O-methyltransferace (COMT) and by monoamine oxidase
(MAO) in which homovanillic acid is formed (HVA) (4). However, the primary way DA
is removed from the synapse is by the reuptake of DA back into the presynaptic neuron
through the action of the dopamine transporter (DAT). DA can then be repackaged into
vesicles, awaiting another round of vesicular release. This process is depicted in the
schematic diagram in Figure 1.
Dopamine Pathways and the Hypothesis of Reward
Much of what is known about dopaminergic pathways and behavior comes from
anatomical studies that used fluorescence histochemical methods to detect catecholamine
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Figure 1: Schematic diagram of dopaminergic neurotransmission. Dopamine (gold
circles) is synthetize and packed into synaptic vesicles (light blue) by the vesicular
monoamine transporter 2 (VMAT2) (pink rods). Upon an action potential, synaptic
vesicles dock at the plasma membrane of the presynaptic neuron and releases dopamine
into the synaptic cleft. Dopamine then binds the dopamine receptors (green cylinders) on
the postsynaptic neuron, resulting in dopaminergic neurotransmission (yellow lightning
bolt). Dopamine can also bind to dopamine autoreceptors on the presynaptic neuron
(green cylinders). Dopaminergic neurotransmission is terminated when dopamine is
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Figure 1 continued: removed from the synapse by the dopamine transporter (purple
trapezoids). Once dopamine is taken up into the presynaptic neuron, it is repackaged into
synaptic vesicles waiting for another round of vesicular release.
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neurons (6–8). From these studies and others, the major dopamine-mediate pathways
were discovered. It was determined that there were four major trajectories of midbrain
dopamine neurons, each forming the major dopaminergic pathways (Figure 2). The
mesolimbic pathway projects from the ventral tegmental area (VTA) to the limbic system
in the nucleus accumbens. These neurons are involved in reward and pleasure pathways
and have been associated with diseases such as schizophrenia, attention deficit
hyperactivity disorder (ADHD), and addiction. The nigrostriatal pathway projects from
the substantia nigra to the striatum in the basal ganglia. These neurons are important for
movement and motor control and have been associated with Parkinson’s disease. The
tuberinfundibular pathway extends from the hypothalamus to the posterior pituitary.
These neurons are important for the inhibition of prolactin secretion, and have been
associated with hyperprolactinaemia disorder. Finally, the mesocortical pathway projects
from the VTA to the frontal cortex. These neurons are important for motivation, emotion,
and attention, therefore associated disorders include schizophrenia, ADHD, and
addiction.
Initial electrical stimulation experiments on rats in the 1950s revealed that the
brain has specialized centers that control reward functions (9). Additional studies
determined that the dopaminergic system was sensitive to electrical self-stimulation in
the midbrain from dopaminergic neurons found in the limbic regions. Studies have shown
synaptic DA is not only increased by natural rewards such as food, water, and sex, but
also by drugs such as cocaine (10, 11). Furthermore, studies have found cocaine selfadministration in animals is dependent on the presence of intact mesolimbic neurons (12),

5

Figure 2: Dopaminergic pathways in the brain. Dopamine neurons projecting from the
VTA to the nucleus accumbens form the mesolimbic pathway (red). Dopamine neurons
projecting from the VTA to the frontal cortex form the mesocortical pathway (blue).
Dopamine neurons projecting from the substania nigra to the striatum form the nigrostrial
pathway (purple). The tuberinfundibular pathway (green) extends from the hypothalamus
to the posterior pituitary. Image modified from Okinawa Institute of Science and
Technology (OIST), Okinawa, Japan; with permission
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thus it is thought that the mesolimbocortical pathways are important for mediating
reinforcement processes of cocaine (13, 14).Together, these studies support the dopamine
hypothesis of reward, that suggest drugs of abuse are rewarding due to the increase in DA
in the mesolimbic system (13).
To further study the dopamine hypothesis, investigators observed a DAT
knockout (KO) mouse (15). In this model, disruption of the mouse DAT gene resulted in
spontaneous hyperlocomotion, signifying the importance of DAT in the dopaminergic
system (15). In DAT KO mice, DA remained in the extracellular space 100 times longer
than wild-type (WT) animals, suggesting clearance by diffusion. Investigators concluded
that in the WT animals, DA was cleared faster due to the presence of DAT, suggesting
DAT is the key factor in controlling synaptic dopamine levels and ending
neurotransmission. From these studies it was also demonstrated that DAT was the target
of these psychostimulant drugs including cocaine and amphetamines (15).
However, other studies suggest more than one system may be important for
reward. Rocha et al. found DAT KO mice self-administered cocaine (16), while others
have found DAT KO mice displayed cocaine-conditioned place preference (17).
Together, these studies suggested the possibility of other systems such as the serotonergic
system that may be involved in the rewarding effects of cocaine. To further study this
concept, serotonin (SERT) KO mice were generated to evaluate the serotonergic system
in reward pathways. SERT KO mice also displayed cocaine-conditioned place preference
(17), however, the combined DAT/SERT KO mice did not. In contrast, norepinephrine
(NET)/SERT KO mice and NET/DAT KO mice still displayed cocaine-conditioned place
preference (18), strengthening the argument that SERT may also be involved in the
7

reward pathways. The DAT KO mice were shown to have many adaptive changes
including reduction in DA, tyrosine hydroxylase, and D1 and D2 dopamine receptor
levels (15), suggesting adaptive changes may alter the normal reward pathways.
To overcome the adaptive changes observed with the DAT KO mouse, a DAT
knock-in mouse line carrying a cocaine-insensitive but functional DAT was created (19).
A triple mutations made in TMD 2 resulted in a 69-fold reduction in cocaine inhibition,
while nearly 50% of DAT was retained compared to WT DAT (19). Furthermore, the
cocaine insensitive knock-in mice displayed abolished cocaine self-administration and
cocaine reward as measured by conditioned place preference (20). These results support
the dopamine hypothesis, suggesting that DAT is necessary for cocaine reward in mice
with a fully functional DAT (20).
The Dopamine Transporter
The solute carrier 6 (SLC6) are a family of secondary active co-transporters that
use extracellular sodium and chloride as a driving force for substrate translocation (21).
This family is divided into four subclasses based on sequence similarity and substrate
specificity (22). The subfamilies include the neurotransmitter transporters (NTT), the
amino acid transporters, creatine transporters, and osmolyte transporters. Specifically, the
NTT family includes three γ-aminobutyric acid (GABA) transporters (GAT), two glycine
transporters (GLY) and the monoamines, SERT, NET, and DAT.
DAT is a plasma membrane protein expressed in dopaminergic neurons and is
essential for regulating dopaminergic neurotransmission. Molecular cloning of DAT has
been done in several species including human, rat, mouse, monkey, Drosophila
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melanogaster, and Caenorhabditis elegans. From these studies the primary sequence of
human (h) and rat (r) DAT is predicted to be 620 and 619 amino acids, respectively, with
hDAT containing an extra glycine at position 199 (23). The predicted structure in
mammalian DAT includes 12 transmembrane spanning domains, intracellular termini,
and a large extracellular loop (EL) between TMD 3 and 4 that contains four glycosylation
sites (23–26) (Figure 3). Additionally, four zinc coordinating residues have been
identified that are important for stabilizing the outward facing conformation of DAT,
acting as a DA uptake inhibitor (27, 28). The zinc coordinating residues found in both
EL2 and EL4, are H193 (EL2), D206 (EL2), H375 (EL4), and E396 (EL4) on hDAT (27,
28).
DAT is also modified by many posttranslational modification found throughout
the protein. The posttranslational modifications include phosphorylation and
ubiquitylation on the N-terminal tail, glycosylation on EL2, and palmitoylation on the C
terminus (discussed in future section) (Figure 3). Together these posttranslational
modifications affect the regulation, function, and structure of DAT.
Ubiquitylation is a posttranslational modification in which an ubiquitin group is
added to a lysine residue. Mass spectrometry analyses of DAT indicated constitutive
ubiquitylation of DAT, with an increase in DAT ubiquitylation upon PKC activation.
(29). Ubiquitylation of other transmembrane proteins was found to be important as a
sorting signal for endocytosis and lysosomal degradation; therefore, experiments were
conducted to determine if this was also true for DAT (30). A triple mutation of Lys19,
Lys27, and Lys35 in hDAT on the N-terminal tail resulted in abolished PKC dependent
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Figure 3: Schematic diagram of the rat dopamine transporter. The structure contains 12
transmembrane domains with N- and C-termini intracellularly oriented. The blue residues
represent the transmembrane domains. The large extracellular loop (EL) 2 contains the
four glycosylation sites and the N-terminal tail contains two ubiquitylation sites, depicted
in yellow. The zinc coordination sites found in EL2 and EL4 are represented by red. The
PKC dependent serine phosphorylation sites and the threonine proline-directed
phosphorylation site are depicted in blue, with the proline represented by a green residue.
The blue cysteine residue on the C-terminus denotes the palmitoylation site on rDAT.
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internalization, suggesting the ubiquitin moieties conjugated to DAT are important for
interactions with the endocytic machinery (30).
DAT is also heavily glycosylated protein, with the sugars attached to asparagine
residues in EL2 (31). Research has shown glycosylation of DAT is important for
trafficking and targeting DAT to the cell (32, 33). Furthermore, proper DAT folding was
found to be facilitated by a disulfide bond in EL2 between cysteines 180 and 189 (34).
This bond was found to be important for proper function of DAT (34).
Studies have also shown that DAT is a phosphoprotein (35–37). This
posttranslational modification on DAT affects DAT function and is regulated by protein
kinases, suggesting another mechanism for temporal and spatial control of synaptic
transmitter levels in dopaminergic signaling. Through phosphoamino acid and proteasebased peptide mapping analysis, the direct region of DAT phosphorylation in rat brain
tissue was determined (38). Results identified one or more serines on the N terminal tail
to be the major sites of both basal and stimulated phosphorylation (38). Additional
studies identified the cluster of serines present within the first 21 N-terminal residues to
be the site where the majority of basal, PKC-induced, and amphetamine-induced
phosphorylation occurs (38–40). Through mutagenic studies, serine 7 was identified as
the major site of PKC dependent phosphorylation in both rat striatal DAT and
heterologous cells expressing rat and human DAT (41). Interestingly, a mutation at serine
7 resulted in decreased binding affinity for a cocaine analog, further suggesting
phosphorylation at serine 7 is important for regulation transporter conformation (41).
An additional phosphorylation site on DAT was also determined to be important
for DAT function (37). Studies identified DAT to be phosphorylated at residue Thr53 in
11

rat and mouse striatum, as well as in heterologous cells (42). Mutagenic studies at
position 53 resulted in reduced DA transporter Vmax, suggesting the importance of this
residue in transporter kinetics (42). This site is different from the PKC phosphorylation
site since the Thr53 residue is followed by a proline, making it specific for prolinedirected kinases, such as extracellular signal regulated kinase (ERK). Phosphorylation of
proline-directed sites are characterized by alterations in protein structure due to the
protein being regulated by cis-trans isomerization of the phosphoacceptor-prolyl peptide
bond (43), suggesting Thr53 may play a role in the transporter function by affecting the
conformation of the protein.
The Structure and Transport Mechanism
Prior to the first high resolution X-ray crystal structure of the bacterial homolog
of the SLC6 transporters, most of the structural understanding was based on observations
and mutagenesis studies. However, that changed in 2005, when the leucine transporter
(LeuT) from the thermophile bacterium Aquifex aeolicus was crystalized with the
substrate leucine and two sodium ions bound (44). For the first time, this prokaryotic
homolog gave insight into the transporters topology and secondary structure. The
crystalized structure confirmed many predictions by revealing 12 TMD connected by
short intracellular and extracellular loops, in addition to intracellular N and C termini.
The overall LeuT structure is asymmetric with two similar structural motifs arranged by a
pseudosymmetric inverted repeat architecture. The 5 + 5 + 2 architecture shows TMDs 15 and 6-10 to form helical bundles that are antiparallel, resulting in a pseudo two fold
axis symmetry. The TMDs pack together in a helix bundle to form two distinct regions of
the transporter, the interior core, and the outer region. The inner core is formed by
12

TMD1, TMD3, TMD6, and TMD8, together these TMDs form the central substrate
binding site (S1) as well as the Na+ binding sites. Overall, LeuT and SLC6 transporters
share 20-25% sequence identity. However, the central core that is important for transport
and substrate binding share a high sequence identity of about 55-67% (44, 45).
Furthermore, 7 of the 11 residues in LeuT that have direct interactions with the substrate
are conserved in all nine mammalian neurotransmitter transporters, suggesting the S1 site
is structurally conserved between LeuT and SLC6 transporters (21). This finding is
supported by experimental evidence also identifying the S1 residues (45–48).
Although the LeuT structure is the basis for the SLC6 family of transporters it is
important to note there are several differences between the prokaryotic and eukaryotic
SLC6 transporters (44). The eukaryotic transporter has much longer intracellular N-and
C-termini; a longer EL2 loop which contains a disulfide bond and glycosylation sites; and
finally several posttranslational modifications that affect the regulation and function of
the transporter. Prior to the LeuT crystal structure it was suggested from sequence
analysis and biochemical approaches that the monoamine family included these important
posttranslational modifications (33, 49). Although models of eukaryotic transporters
based on LeuT provided insight into substrate binding, there are still many questions
regarding the structure and function. In 2013, the Gouaux lab crystalized the Drosophila
melanogaster dopamine transporter (dDAT) (50) (Figure 4A). The structure of dDAT
was crystallized at a 3.0 A resolution bound to the tricyclic antidepressant nortriptyline.
The dDAT has over 50% sequence homology with the mammalian transporters DAT,
NET, and SERT, making it a very useful tool. While dDAT was similar to LeuT there
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Figure 4. Crystal structure of the dopamine transporter. (A) x-ray crystal structure of the
Drosophila melanogaster dopamine transporter (dDAT) in complex with the TCA
nortriptyline. The structure also shows a cholesterol molecule wedged into a groove formed
by TMD1, TMD5, and TMD7. (B) Locations of the open extracellular gate (red box),
closed intracellular gate (blue box), and C-terminal latch (green box). Image modified from
A. Penmastal, K.H. Wang, and E. Gouaux. 2013. X-ray structure of the dopamine
transporter in complex with tricyclic antidepressant. Nature 503(7474): 85-90, with
permission.
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was additional information provided by this structure. The dDAT structure determined
that a cholesterol molecule was wedged in a groove formed by TMD1, TMD5, and
TMD7, likely important for stabilizing the outward-open conformation (51, 52).The
structure also revealed two attributes on the C-terminus. First the crystal structure
revealed a kink in TMD12 halfway across the membrane bilayer at Pro572 that causes the
intracellular portion of the helix to turn away from the transporter. The structure also
revealed a latch-like C-terminal helix thought to be important for interactions with the
cytoplasmic face of the transporter. The C-terminal helix was also found to interact with
IL1, which interacts with TMD1a (Figure 4B). The close proximal interaction with the
cytoplasmic gate suggests the C-terminal helix may be important for modulating
transport activity (50). Together, the LeuT and dDAT crystal structures provided
important information about the structures and mechanism of SLC6 transporters that was
previously unknown.
The process through which DAT transports substrate from the outside of the cell
to the inside of the cell is known as the alternating access mechanism. The alternating
access mechanism was first coined in 1966 by Dr. Oleg Jardetzky (53). This term was
used to describe the conformational changes transporters use to alternate through when
transporting substrate from the extracellular space into the cytoplasm. Now with a more
complex understanding, it is widely accepted that membrane proteins, including SLC6
proteins, transport their substrate through a series of conformational changes via the
alternative access mechanism (21, 54) (Figure 5). The transition of these conformations
dictate the transport capacity.
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Figure 5: The alternating access mechanism model of the dopamine transporter. A
schematic representation of the conformations of DAT important for translocation of
substrate from the extracellular space to the cytoplasm. (A) The transporter in an outward
facing conformation allowing substrate to bind. The transporter is facing the extracellular
space with the extracellular gate open and the intracellular gate closed. (B) The transporter
is an outward occluded (C) or inward occluded configuration in which ions and substrate
are in there appropriate binding sites, both the extracellular and intracellular gates are
closed. (D) Inward facing conformation. The extracellular gate is closed while the
intracellular gate opens allowing substrate and ions to be released into the cytoplasm of the
cell. Once the substrate is released, the transporter will return to the outward facing
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Figure 5 continued: conformation awaiting the next round of translocation. Image modified
from Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ,
Stromgaard K, and Gether U. 2011. SLC6 neurotransmitter transporters: structure,
function, and regulation Pharmacol Rev 63(3):585-640, with permission.
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DAT cycles through outward and inward facing conformations that allow for
binding of substrates and release into the cytoplasm. Initially, when DAT is in the
outward open conformation, the extracellular gate is open allowing substrate to bind. At
the same time, the intracellular gate is closed, sealing off the cytoplasmic side from the
aqueous extracellular environment (Figure 5A). Once the substrate is bound, the
transporter transitions into an occluded state in which both the extracellular and
intracellular gates are closed (Figure 5B and C). In a similar manner, the intracellular gate
is opened while the extracellular gate is closed thus releasing the substrate into the cell
(Figure 5D). Once the substrate has been released the transporter returns to the lowest
energy conformation, outward facing, waiting for the next substrate to bind. The gating
residues responsible for the transition of conformations are based on the LeuT structure
(44). The extracellular gate is formed by the ionic interaction of Arg85 and Asp477.
Additionally, Tyr156 and Phe320 form aromatic lids that act as a secondary external gate,
preventing access to the central substrate binding site. The intracellular gate is formed by
the ionic interaction of Arg60, Ser334, Tyr335, and Asp436. Additionally, Trp63
stabilizes the intracellular halves of TMDs 1 and 6. There have been several proposed
models for the translocation of substrate in the transporter core during the outward to
inward transition. One model suggests the unwound region in the middle of TMD1 and
TMD6 acts as a flexible hinge that can move the intracellular halves independently
during a conformational outward to inward transition (21, 44, 55, 56). Another proposed
model suggests TMD1 and TMD6, along with TMD2 and TMD7, form a rigid body that
rocks back and forth allowing the transition between outward and inward facing
conformations (21, 54). The conformation of the transporter is important for kinetics
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regulation and functionality. Changes in conformation can result in reverse translocation
of substrate (efflux), which requires binding and outward translocation of intracellular
DA (57, 58).
Regulation of DAT by Psychostimulants- Blockers and Substrates
DAT is the target of many clinically used drugs, such as bupropion (Wellbutrin®,
an antidepressant), methylphenidate (Ritalin®, ADHD medication), and mazindol
(Mazindor®, an appetite suppressant) (21, 59). As well, DAT is also the main site of
action for powerful addictive psychostimulants including cocaine and methamphetamine
(METH). These drugs work by disrupting normal dopaminergic neurotransmission by
either blocking DAT or increasing DA efflux. Both conditions lead to prolonged
dopaminergic signaling resulting in the euphoric feeling associated with drug addiction
(60). Neurochemical imaging studies have shown chronic use of cocaine or METH can
lead to long-term impacts on DAT levels by mechanisms that are not fully understood
(61, 62). In addition to the direct effects on DA transports, multiple studies have shown
that DAT activity is regulated by blockers and substrates after pretreatment followed by
washout, indicating drugs of abuse can affect dopaminergic neurotransmission even after
the removal of the drugs.
The two classifications of drugs that act on DAT are substrates and blockers.
Drugs like cocaine act as blockers by binding to DAT and inhibiting the reuptake of DA
from the synapse, increasing synaptic DA levels. Cocaine has been shown to effect DAT
regulation in postmortem samples of human cocaine addicts (63), suggesting chronic
abuse of cocaine can cause long term effects in humans. In contrast to blockers, AMPH
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and METH act as DAT substrates, competing with endogenous DA for transport and
inducing DA efflux through transporter reversal (59, 64–67).METH and AMPH have
been shown to have pronounced alterations on DAT trafficking and DA uptake levels
(59, 64–68). These effects on transport and surface expression have been shown to be
blocked by cocaine, indicating these substrates are activity transported into the cell by
DAT (59, 64) Studies show short time exposure (less than 1 minute) to AMPH results in
DAT recruitment to the plasma membrane and an increase in transport (69–71). It is
thought this rapid recruitment of DAT is important for clearance of extracellular DA
induced by the drug (69, 71). In contrast longer exposure to METH and AMPH have
resulted in DAT downregulation and endocytosis of DAT (39, 71–73). Downregulation
after longer substrate exposure times is thought to be a neuroprotective mechanism by
limiting the cytosolic accumulation of DA and its neurotoxic metabolites.
AMPH-stimulated downregulation is thought to occur by both kinetic and
endocytotic downregulation mechanisms, because AMPH-induced downregulation has
been found in the absence of endocytosis (72, 74). Research has shown that METH-andAMPH-induced DAT phosphorylation can be blocked by inhibition of PKC,
demonstrating PKC is involved in the regulation of DAT by substrates (39, 75, 76).
Likewise, METH and PKC induced DAT phosphorylation can be reduced by the
truncation of the first 21 residues in DAT, suggesting METH and PKC-mediated
phosphorylation occur in the same region of DAT. AMPH and METH have also been
shown to stimulate DA efflux (59, 64–67) , however this mechanism is poorly
understood. Additionally, AMPH stimulated efflux can be impaired when deletions of
distal N terminal serines or disruption of the CaMKIIa binding domain occur (77, 78),
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though it is not clear how the N-terminus and CaMKIIa operate together for AMPH
induced efflux.
DAT Protein-Protein Interactions
It is well known that DAT is not an isolated protein, but rather a highly regulated
multiprotein complex formed by protein-protein interactions (79) that regulate
trafficking and function of DAT. Multiple proteins are known to bind and interact with
both the N-and C-termini of the transporter (Figure 6). Regulatory partners discovered to
interact with the N-terminus include Syntaxin 1A (Syn1A) and D2 receptors. Using a
yeast two-hybrid system, Syn1A (80) was revealed to have novel interactions with DAT.
Syn1A is a member of the soluble N-ethylmaleimide sensitive factor attachment protein
receptor (SNARE) protein family and has been shown to mediate AMPH-induced DA
efflux in murine synaptosomes and in C. elegans to regulate DAT1 ion channel activity
(81, 82). Together, these studies have identified the Syn1A binding site on DAT to be on
the N-terminus of DAT at residues 1-33. (81, 82). Additional studies aimed at
understanding the regulation of Syn1A and DAT found that an overexpression of Syn1A
reduces transport Vmax and affects surface expression (83). Furthermore, cleavage of
Syn1A, with the protease Botulinum Neurotoxin C (BoNT/C) increases DA transport
Vmax and reduced DAT phosphorylation, suggesting Syn1A interaction with DAT may
affect regulatory mechanism important for DAT function (84). Another protein known to
directly interact with DAT is the G-protein coupled receptor (GPCR) family member,
dopamine receptor, D2. D2 receptors function as autoreceptors allowing an inhibitory
feedback mechanism by altering DA synthesis, release, and reuptake in response to
increasing levels of extracellular DA found in the synapse. D2 and DAT interactions
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involve the N-terminus of DAT and the third intracellular loop of the D2 receptor (85).
The physical interaction facilitates the recruitment of DAT to the plasma membrane
resulting in enhance DA uptake (85).
Other DAT regulatory partners that interact with DAT near the C-terminus of the
transporter include, protein interacting with kinase 1 (PICK1), Rin1 (Ras-like in
neurons), flotillin 1 (Flot1),calcium-calmodulin-dependent protein kinase (CaMKIIa),
Parkin, and α-synuclein (α-syn) (77, 86–91). PICK1 is a PSD-95/Discs- larger/ZO-1
(PDZ)-domain containing protein that is important for clustering receptors and ion
channels (92). Interestingly, hDAT contains a PDZ binding sequence (LKV) at the end of
the C-terminus. PICK1 was a candidate for a regulatory interaction of DAT based on a
yeast two-hybrid screening (86). Originally, the interaction between PICK1 and DAT
was thought to be important for endoplasmic reticulum (ER) export of DAT. Initial
studies, found the truncation of C terminal of DAT resulted in ER retention and impaired
surface expression (86). However, it was later demonstrated that the PDZ-binding
interactions of DAT was not necessary nor sufficient for DAT surface expression in
heterologous cells (93). Additional in vivo studies determined DAT knock-in mice with
disrupted PDZ-binding motifs had a dramatic loss of DAT expression in the striatum,
suggesting PDZ domain interactions were critical for synaptic distribution of DAT in
order to maintain DA homeostasis (94).
Rin was identified by yeast two-hybrid screening to interact with DAT was (88).
Previous studies determined residues 587-596 (FREKLAYA) encoded an endocytic
regulatory domain that modulates both basal and PKC-enhanced DAT internalization
rates; (87). Therefore, studies aimed at understanding where Rin binds were performed. It
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Figure 6: DAT protein-protein interactions. The transporter is positioned in the membrane
lipid bilayer with the N-and-C termini. The various binding partners of DAT are depicted
based on where they bind or interact with DAT. Syntaxin 1A (Syn1A), dopamine
autoreceptor2 (D2), protein interacting with kinase 1 (PICK1), Rin1 (Ras-like in neurons),
flotillin 1 (Flot1), calcium-calmodulin-dependent protein kinase (CaMKIIa), Parkin, and
α-synuclein (α-syn). Modified image from Vaughan RA and Foster JD. Mechanisms of
dopamine transporter regulation in normal and disease states 2013. Trends in
Pharmacological Sciences 34(9):489-496, with permission
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was determined that Rin interacts with DAT at residues 587-590 on the C-terminus in a
PKC-regulated manner, which is required for PKC-mediated DAT internalization (88).
Flot1 also known as Reggie 2 is a membrane raft protein whose binding site on
DAT is currently unknown (95). Flot1 is highly conserved and expressed in the nervous
system and thought to be important for endocytosis (96). This protein associates with the
membrane in a cholesterol-dependent manner, resulting in hetro-oligomers and
microdomains in the plasma membrane (97). Current, studies suggest Flot1 is required for
PKC-triggered endocytosis of DAT (95). Furthermore, it was determined that DAT
complexes with palmitoylated Flot1 in a PKC-dependent manner and a conserved serine
residue of Flot1 is required for PKC-mediated internalization. It was also demonstrated
that Flot1 is important to maintain DAT in membrane rafts, suggesting DAT membrane
microdomain localization may be important for endocytosis of DAT; however unknown at
this time (95).
CaMKIIa binds to the distal C-terminus of DAT at residues 612-617 (77) and has
been shown to play an important role in AMPH-mediated efflux of DA in heterologous
cells and dopaminergic neurons. Fog et. al. demonstrated in vitro that CaMKIIa is
responsible for phosphorylating the serines found on the distal N terminus (77). A mutation
made on the C-terminus impaired CaMKIIa binding and AMPH-induced efflux. Thus
suggesting CaMKIIa binding to DAT on the C-terminus facilitates phosphorylation of
DAT on the N terminus.
Parkin and α-syn are two proteins associated with Parkinson’s disease. Initial
studies determined that α-syn interacts with the carboxyl tail of hDAT, resulting in the
formation of membrane clustering, thereby increasing DA uptake and DA induced
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cellular apoptosis (98).This was proposed to be a possible mechanism for the degradation
of dopaminergic nerve terminal is Parkinson’s disease (98). It was later determined that
parkin, an E2-dependent E3 protein ubiquitin ligase, exerts protective effects against DAinduced α-syn toxicity (90). This study established that parkin impairs the α-syn and
DAT complex by interacting with the carboxyl tail of DAT and blocking α-syn induced
enhancement of DAT surface expression and DA uptake (90).
It is known that neurotransmitter transporters exist as oligomeric complexes in
cell, however the function of these complexes are unclear. SERT was initially detected by
co-immunoprecipitation to form oligomers (99), and it was later discovered that DAT
also forms dimers (33) . Additional studies using fluorescence resonance energy transfer
(FRET) revealed DAT oligomers are formed in the ER and are continually maintained at
the cell surface and during trafficking events between the plasma membrane and
endosomes (100). Furthermore, oligomer formation is important for proper targeting of
newly synthesized DATs to the plasma membrane (101). The LeuT crystal structure
determined the dimer interface was formed by EL2, TM9, and TMD12 (44).
More recently, studies suggest a role for oligomerization in regulating DA
transport function. It was discovered that substrates of DAT including DA and
amphetamine, are involved in dissociation of DAT oligomers, shifting the distribution of
surface DAT from oligomers to more monomers (102). From these studies, it was
suggested that substrate induced internalization could be mediated by DAT monomers
(102). Additionally, studies have found the formation of oligomers affects the binding
properties of DAT, suggesting cooperativity within an oligomer (103).
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Regulation of DAT by lipids
Integral membrane proteins can segregate into plasma microdomains known as
membrane rafts. Membrane rafts are small 10-200 nm domains that are highly enriched in
cholesterol and sphingolipids (104). These microdomains are important for scaffolding
processes such as receptor signaling. These small, highly dynamic rafts can sometimes
be stabilized to form larger microdomains through protein-protein and lipid-protein
interactions (104). Several membrane proteins are functionally regulated through their
association with membrane rafts, including serotonin, norepinephrine, and glutamate
transporters (105–107).
DAT has also been found to be associated with membrane microdomains, with a
relatively equal distribution between membrane rafts and non-raft domains (108, 109).
Studies have shown cholesterol is important for transport activity of DAT. Depletion of
cholesterol by methyl β cyclodextrin (mβCD) results in a significant decrease in DA
uptake (108, 109), lowering both DAT’s affinity for DA and the Vmax (109). Membrane
mobility and microdomain association of DAT has also studied by fluorescence recovery
after photobleaching (FRAP). Adkins et. al demonstrated that cholesterol depletion
significantly reduces membrane lateral diffusion of DAT, indicating DAT is more mobile
(109). Together these studies indicate association of DAT with lipid microdomains
regulates both lateral membrane mobility of the transporter and transport capacity.
Additional studies have focused on the direct interaction of cholesterol and DAT.
Research has shown that cholesterol can modulate the transporter into an outward facing
conformation with moderate increases in membrane cholesterol content, allowing for
increased binding sites for radiolabeled cocaine analogs and enhanced sulfhydryl
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accessibility to cysteines (51). Additional studies have shown that disruption of
membrane cholesterol by mβCD in both raft and non-raft membrane domains results in
reduced efflux rate (110). Together, these studies suggest an important role for direct
DAT-cholesterol interactions, vital for the regulation of transporter function (51, 110).
Cholesterol can interact with many proteins through Cholesterol Recognition
Amino Acid Consensus (CRAC) motifs The specific sequences L/V-X(1-5)-Y-X(1-5)-K/R
can bind sterols via hydrophobic aromatic and H-bonding interactions (111). These
particular CRAC motifs are found in DAT in TMD1, TMD4, TMD6, TMD7, TMD12,
and the C terminus (68). These sequences are also highly conserved in NET and SERT. It
is unknown if theses CRAC motifs are important for interactions between DAT and
cholesterol binding, however, it would suggest another mechanism for DAT regulation
via cholesterol.
Protein Palmitoylation
Many proteins, especially those associated with membrane rafts, are modified by
palmitoylation. S-palmitoylation consists of a thioesterification of a 16-carbon fatty acid
(palmitate) on a specific cysteine residue. Palmitoylation increases protein
hydrophobicity, mediates protein-lipid bilayer interactions, and can alter protein sorting,
function, and regulation (112–116). Specifically for membrane proteins, palmitoylation
has been shown to affect the conformation of TMDs by hydrophobic matching, promote
association with lipid microdomains, promote the formation of protein complexes, and
affect the interplay with other posttranslational modifications (117–121) (Figure 7).
Unlike myristoylation and prenylation, which are stable and permanent lipid
modifications, the thioester bond that links palmitate to the protein is labile and
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Figure 7: Effects of palmitoylation on transmembrane proteins. (A) Palmitoylation (red
rectangle) of transmembrane proteins (yellow cylinder), can promote protein-protein
interactions by modifying the conformation of the protein. (B) Palmitoylation can inhibit
protein-protein interactions by changing the conformation of the protein. (C).
Palmitoylation can promote proteins to associate with specific microdomains. (D)
Palmitoylation group change the conformation of the protein by tilting the TMD. Image
modified from Charollais J & Van Der Goot GF. 2009: Palmitoylation of membrane
proteins Molecular Membrane Biology. 26(1-2): 55-66, with permission.
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reversible. For many proteins, cycles of palmitoylation and depalmitoylation occur
throughout their lifetime (122). Palmitoylation-depalmitoylation cycles can be
constitutive or dynamically regulated by signaling events (123, 124), like
phosphorylation.
Palmitoylation is catalyzed by palmitoyl acyltransferases (PATs) while
depalmitoylation is catalyzed by palmitoyl-protein thioesterases (PPTs). PATs are polytopic membrane proteins (125, 126), suggesting that palmitoylation reactions generally
occur near the cytosol membrane interface (127). Systematic screening has recently
identified a large family of PAT enzymes in the human genome (112, 125, 128–130),
also known as the DHHC enzymes. The PAT enzymes are characterized by the presences
of a 50 amino acid cysteine rich domain that contains a conserved amino acid sequence
Asp-His-His-Cys (DHHC) in the active site (130). Besides the DHHC core domain, these
proteins also contain four or more TMDs, with the DHHC domain usually located
between TMD2 and TMD3 (113, 126, 131, 132) (Figure 8). Additionally, some DHHC
enzymes have individual protein-protein interacting domains such as a PDZ-binding
domain (DHHC3 and DHHC8); SH3 domain (DHHC6); or ankyrin repeats (DHHC13
and DHHC17) (113, 126, 131) (Figure 6). Additionally, The 23 PATs have varied tissue
distributions and intracellular localizations, with most being localized to the Golgi
apparatus, endoplasmic reticulum, or the plasma membrane (132, 133). The large number
of DHHC proteins along with their localization to specific cellular compartments
suggests that palmitoylation machinery is tightly regulated and highly controlled.
In contrast to the large number of DHHC enzymes that catalyze palmitoylation,
few depalmitoylating enzymes have been discovered. Depalmitoylating enzymes include
29

Figure 8: Domain structure of DHHC enzymes found in the brain. A representative diagram
of DHHC (Asp-His-His-Cys) proteins. DHHC enzymes contain four or more
transmembrane domains (pink squares) and a conserved cysteine rich domain (CRD)
containing a DHHC motif (yellow rectangles), which is essential for palmitoylation. Some
enzymes have additional motifs including a PDZ binding domain (orange cylinders) at the
C terminus for DHHC3 and DHHC8, and ankyrin repeats (green rectangles) for and
DHHC17. Image modified from Koryckaa J, Lacha Am Hegerb E, Boguslawskab DM,
Wolnya M, Toporkiewixza M, Augoffc K, Korzeniewskid J, and Sikorskia AF 2012.
Human DHHC proteins: A spotlight on the hidden player of palmitoylation European
Journal of Cell Biology 91: 107-117, with permission
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acyl protein thioesterases 1 (APT1), APT2, and APT1-like and and palmitoyl protein
thioesterases 1 (PPT1) and PPT2. APTs are cytosolic enzyme that removes palmitate
from proteins on the cytosolic membranes (122). PPT1 and PPT2 are lysosomal proteins
(134) that are important for depalmitoylating proteins during protein degradation.
Because PPT1 and PPT are lysosomal proteins they do not directly act on cytosolic
palmitoylated proteins (135). However, PPT1 has been detected in the presynaptic
compartments, where it is suggested to be important for maintaining the synaptic vesicle
pool (136).
There is no defined consensus sequences for substrate palmitoylation, however,
palmitoylated proteins do share common features (127). Palmitoylated proteins often
have other lipid modifications such as myristoylation or prenylation, located near the site
of palmitoylation. Also palmitoylated Cys residues are located in the cytoplasmic regions
surrounding TMDs and are surrounded by amino acids that are basic or hydrophobic. The
mechanism by which a substrate protein is palmitoylated occurs in a two-step process
(137). First the DHHC enzyme modifies itself with palmitate, in a process known as
autoacylation, then the enzyme transfers the palmitate from itself onto the substrate
protein (138, 139). Until recently it was unknown where autoacylation occurred. Mass
spectrometry studies have now identified the Cys in the DHHC motif as the site of
autoacylation (140).
Although the enzymes that control palmitoylation, have been identified, little is
currently known regarding mutations or regulatory abnormities associated with disease
states. However, there are a few PAT enzymes that have been associated with
neurological disorders. DHHC8 is the most well studied DHHC enzyme and has been
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connected to schizophrenia (141, 142). A high risk of developing schizophrenia is
associated with microdeletions of human chromosome 22q11.22 locus (141, 142). This
deleted region also includes the DHHC8 gene. Interestingly, the deficits linked to the
microdeletion could be rescued by expression of the active DHHC8 protein (141),
indicating the importance of palmitoylation. Furthermore, PATs represent a potential
therapeutic strategy for some diseases.
Huntington’s disease is also another neurological disorder linked to DHHC
enzymes(143). Huntington’s disease is caused by the expansion of polyglutamine
(polyQ) repeats in the huntingtin protein (143, 144). Additionally, Huntington’s disease is
characterized by the accumulation of protein aggregates that are formed by the misfolded
polyQ repeat-containing proteins. Normally, the protein huntingtin is palmitoylated by
DHHC17, however the polyQ expression of huntingtin disrupts the interaction with
DHHC17, resulting in decreased palmitoylation (144). Reduced palmitoylation causes
accumulation of protein aggregates in inclusions which may be correlated with cell
toxicity (132, 143, 144).
Other DHHC enzymes linked to neurological disease include DHHC9 and
DHHC15. Both enzymes have been associated with X-linked intellectual disability in
humans (145, 146). Although the exact cause is unknown, mutations in the conserved
DHHC9 and DHHC15 genes have been found in families with the X-linked intellectual
disability phenotypes. Initial studies suggest proper palmitoylation is required for the
temporal and spatial location of proteins in the plasma membrane and Golgi complex.
Loss of palmitoylation alters the distribution of target proteins and is sufficient enough to
cause X-linked intellectual disability (132, 146).
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Depalmitoylation has also been linked to neurodegenerative diseases (147). The
autosomal recessive brain disorder, infantile neuronal ceroid lipofuscinosis is cause by a
mutation of in PPT1(147, 148). Mutations in the lysosomal PPT1 enzyme impairs the
removal of long chain fatty acids from proteins, preventing protein degradation, and
resulting in the accumulating of palmitoylated proteins(124, 144, 148).
DAT Palmitoylation
Our lab demonstrated for the first time that DAT undergoes palmitoylation in both
native and heterologously expressed tissues (149). This modification was blocked with
the treatment of the irreversible PAT inhibitor 2-bromo palmitate (2BP). In this same
study it was determined that 2BP regulates DAT palmitoylation in two distinct ways. A
low dose and shorter 2BP treatments resulted in a significant reduction in DA transport
Vmax with no changes in surface expression. These results indicate reduced DAT
palmitoylation decreases transport kinetic efficiency, affecting short-term regulation of
DAT. A higher dose and longer treatment with 2BP caused DAT protein losses,
indicating DAT palmitoylation is also regulated long-term.
There are five intracellularly oriented cysteines residues that are potential sites of
DAT palmitoylation in rDAT (Cys6, Cys135, Cys341, Cys522, and Cys580). Through
mutagenic studies, it was determined the major site of DAT palmitoylation is at Cys580
in rDAT. Metabolic Labeling of the C580A mutant with [3H]palmitate, reduced DAT
palmitoylation by ~60% compared to the WT protein. The [3H]palmitate signal remaining
on C580A suggests one or more additional site is palmitoylated in rDAT. Additional
studies determined the C580A palmitoylation-deficient mutant still had cocainedisplaceable [3H]DA transport activity that was proportional to the overall expression.
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When immunoblotted, the C580A mutant resulted in low molecular weight degradation
fragments that were not visualized in the WT protein. These fragments were enhanced
when C580A rDAT cells were treated with 2BP, suggesting palmitoylation is important
for opposing DAT degradation. The C580A mutant also displayed increased PMAinduced down-regulation compared to WT, indicating depalmitoylated DAT is more
sensitive to PKC- induced down regulation compared to palmitoylated DAT (149).
More recently our lab has shown palmitoylation to play a reciprocal role with
phosphorylation (150). To study this process, the C580A palmitoylation mutant and the
S7A phosphorylation mutant were assessed for either palmitoylation or phosphorylation
levels of DAT. The C580A mutant had significantly enhanced DAT phosphorylation
levels in comparison to WT. In reverse experiments, the S7A mutant had increased DAT
palmitoylation level when assessed by [3H]palmitate labeling. Together, these mutagenic
studies suggest that both of these posttranslational modifications may be important in
regulating DAT activity. Additional pharmacological experiments were done to confirm
the mutagenic results. In these experiments, cells were treated either with PMA, which
stimulates PKC and thus DAT phosphorylation, or bisindolmaleimide (BIM), which
blocks PMA-stimulated DAT phosphorylation (36). PMA significantly reduced [3H]
palmitate labeling, while treatment with BIM increased it, suggesting palmitoylation and
phosphorylation are working opposite of each other in an unknown mechanism. In
reverse experiments, rat striatal synaptosomes were used to determine the DAT
phosphorylation state in depalmitoylated conditions. Results showed 2BP treatment
caused a significant increase in DAT phosphorylation compared to basal levels. Taken
together, the mutational and pharmacological experiments demonstrate that these
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posttranslational modifications are reciprocally regulated and important for DAT
regulation and function.
Purpose of Current Study
The dopamine transporter has been found to be palmitoylated on the C-terminus at
Cys580 (149). This posttranslational modification is known to regulate diverse aspects of
neuronal protein trafficking and function (132, 151), however its role in DAT function is
poorly understood. DAT palmitoylation was previously found to be inhibited by the nonspecific PAT inhibitor, 2BP. Treatment with 2BP resulted in decreased DA transport
activity and an increase in DAT degradation (149), suggesting palmitoylation controls
one or more functions of DAT.
There are 23 PAT enzymes currently identified in the human genome (112, 125, 128–
130), with some associated with dopaminergic diseases such as schizophrenia (141, 142);
however, the enzymes that catalyze DAT palmitoylation still remain unknown.
Furthermore, psychostimulant drugs such as METH and cocaine are known to act on
DAT, effecting transporter function (69, 70, 73, 75, 76, 152). Nonetheless, the effects of
psychostimulant drugs on DAT palmitoylation still remain unknown. Therefore, we
hypothesized that specific PAT enzymes will drive DAT palmitoylation, controlling
expression, DA transport, and membrane lateral mobility of the transporter. To answer
this question, we co-expressed a specific subset of neuronally-expressed PATs
individually with DAT and assessed DAT palmitoylation using the acyl-biotinyl
exchange method, with some results validated by [3H]palmitic acid labeling. Functional
changes of DAT were also assessed including, total and surface expression, transport
activity, and lateral membrane mobility. Additional studies were also conducted to
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investigate psychostimulant regulation of DAT palmitoylation. Identifying the enzymes
that drive DAT palmitoylation will allow us to better understand the mechanism of
palmitoylation, thus providing critical insight into dysregulation in dopaminergic
disorders and drug addiction.
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CHAPTER II

MATERIALS AND METHODS

Materials
Animals
Male Sprague Dawley rats (200-300g) were obtained from Charles River
Laboratories (Wilmington, MA) and were maintained in compliance with the guidelines
established by the University of North Dakota Institutional Animal Care and Use
committee and the National Institutes of Health.
Reagents
Methyl methanethiosulfonate (MMTS), (N-(6-(biotinamido) hexyl)-3-(2’-pyridyldithio)propionaminde (HPDP biotin), high capacity Neutradvidin resin, Complete Mini
Proteases Inhibitors, DHHC2 antibody, X-treme GENE HD, Lipofectamine2000, OptiMEM, and Trypsin were purchased from Thermofisher Scientific (Waltham, MA). [7,83

H] dopamine (45Ci/mmol) was purchased from Perkin Elmer (Walthman, MA). [9,10-

3

H] palmitic acid was purchased from Moravek (Brea, CA). Protein A Sepharose beads

were purchased from GE Healthcare Life Sciences (Piscataway, NJ). (-)-Cocaine, (-) 2βcarbomethoxy-3β-(4-fluorophenyl) tropane (β-CFT), mazindol, dopamine,
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hydroxylamine, molecular weight markers were purchased from Sigma-Aldrich (St.
Louis, MO). Lewis Lung Carcinoma Porcine Kidney (LLCPK1) cells expressing rDAT
were kindly provided by Dr. Gary Rudnick (Yale University, New Haven, CT). Neuro-2a
(N2a) cells were purchased from American Type Culture Collection (ATTC) (Manassas,
VA). The DHHC constructs were kindly provided by Dr. Masaki Fukata from the
National Institute for Physiological Sciences, Okazaki, Aich Japan. Hemagglutinin
epitope HA.11 monoclonal antibody was purchased from Covance (Emeryville, CA).
DHHC3, DHHC8, DHHC9 antibodies were purchased from Santa Cruz Biotechnology
(Dallas, TX). Transferrin Receptor (TfR) antibody was purchased from BD Biosciences
(San Jose, CA). Alkaline phosphatase conjugated secondary antibody were purchased
from Simga-Aldrich (St. Louis, MO). Polyacrylamide gels were purchased from Lonza
(Rockland, ME). Alkaline phosphatase developing substrate was purchased from BioRad (Hercules, CA). Site directed mutagenesis Quick Change® kit was from Stratagene
(La Jolla, CA). Synthesized oligonucleotides were purchased from Eurofin MWG Operon
(Huntsville, AL). All other chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) or Thermofisher Scientific (Waltham, MA).
Equipment
Centrifuges
Refrigerated Beckman microfuge R or the bench top Microfuge 18 were used for
general lab procedures. The Beckman Avanti J-25, 16.250 and 25.50 rotors were used for
synaptosome preparation and harvesting E.Coli cells for protein and plasmid isolation
purposes. The Beckman J6-MI swinging bucket centrifuge was used to pellet cells and to
prepare cross-linked Protein A Sepharose beads.
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Electrophoresis
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
protein transfers were performed using the Bio-Rad Mini-Protein III electrophoresis
apparatus and the Bio-Rad Mini trans blot electrophoresis transfer cell, respectively.
Electrophoresis and protein transfer was controlled by Fisher Scientific FB300 power
supply. Gels were dried using a Bio-Rad Model 583 gel dryer.
Spectroscopy
Bicinchoninic acid (BCA) protein assays were quantified using the Molecular
Devices SpectraMax 190 plate reader and DNA quantification was performed using
Beckman DU640 spectrophotometer. Incorporation of radioactivity during uptake
experiments were counted using a Packard 1900CA or a Beckman LS6500 liquid
scintillation counter.
Cell Culture and Molecular Biology
Mammalian cell were maintained in a sterile Nuair Class II A/B3 laminar flow
hood, and incubated in a Nuair 2700-30 water jacketed CO2 incubator. All Polymerase
Chain Reactions (PCR) experiments were done in an Eppendorf Mastercycler personal
thermal cycler.
Microscopy
Confocal and Fluorescence recovery after photobleaching (FRAP) experiments
were done using Zeiss 510 META laser scanning confocal microscope.
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Methods
Mammalian Cell Culture
Lewis lung carcinoma-porcine kidney (LLCPK1) cells stably expressing the WT
rat dopamine transporter (rDAT) were maintained with α- minimum essential medium
(AMEM) supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 100 µg/ml
penicillin/streptomycin, and 200ug/ml G418. Neuro-2A cells (N2a) cells were maintained
with α- minimum essential medium (AMEM) supplemented with 10% fetal bovine
serum, 2 mM L-glutamine, 100 µg/ml penicillin/streptomycin. All cells were grown in T75 flasks and maintained at 37°C in a 5% CO2 in the Nuair water-jacketed CO2 incubator.
Transient Transfection and Site Directed Mutagenesis, and Plasmid Transformation
For transient transfection, LLCPK1 or N2a cells were grown to ~70 % confluency
and transfected using X-tremeGENE HD or lipofectamine 2000 transfection reagent and
2 µg of PAT DHHC pEF-BOS-HA tagged plasmid. Cells were incubated for 18-20 hours
followed by harvesting. Site-directed mutagenesis of DHHC2 to DHHA2 was performed
on pEF-BOS-HA plasmid containing Stratagene design primer software was used to
design oligonucleotide primers, which were ordered from MWG operon. QuickChange®
method was used to mutant selected residues C156. A 50 µL reaction mixture included 5
µL of 10X reaction buffer (100 mM KCl, 100 mM NH4SO4, 200 mM Tris-HCl, 20mM
MgSO4, 1% Triton X-100, 1 mg/mL nuclease free BSA, pH 8.8), 8 µL of template DNA
(5 ng/µL), 1.25-1.60 µL of oligonucleotide forward and reverse primers (125 ng), 2µL of
dNTP mix, 32.5 – 31.8 µL of double distilled DNAse free H2O. Addition of 1 µL of pfu
Turbo or pfu Ultra DNA Polymerase (2.5 U/µL) initiated the polymerase chain reaction
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(PCR). PCR cycling parameters included denaturation, annealing, and primer extension.
Denaturation required heating the DNA to 95 ºC for 1 min to render it single stranded.
The annealing step was performed at 55 ºC for 1 min and primer extension was done at
68 ºC for 8 min followed by 15 repeated denaturation, annealing, and primer extension
cycles. Supercoiled double stranded template DNA was degraded by incubation with 1
µL of DpnI restriction enzyme for 18 h at 37 ºC. The generated plasmid was transformed
into Stratagene Giga competent E coli cells. 1-4 µL of ligation mixture was added to 25
µL of competent cells. Cells were placed on ice for 5 min and heat shocked for 30 sec at
42 ºC on a heat block. Tubes were placed on ice for 2 min and 250 µL of SOC media was
added and cells were plated on carbenicillin resistant agar plates for > 16 h at 37 ºC. The
plasmid was isolated using PureYield® Plasmid miniprep System (Promega). DNA was
quantified via Epoch microspot spectrometry and sent to MWG operon (Birmingham,
AL).
Cell Membrane Isolation
LLCPK1 rDAT or N2a cells were grown in 100 mm plates and harvested when
reaching 90% confluency. Cells were washed twice (0.25 M sucrose, 10 mM
tiethanolamine, 10 mM acetic acid, pH 7.8) at 4°C, scraped, and pelleted at 700 X g for 8
mins. Cells were then resuspended in buffer C (0.25 M sucrose, 10 mM triethanolamine,
10 mM acetic acid, 1 mM EDTA, pH 7.8), transferred to a Dounce homogenizer, and
homogenized. Homogenate was centrifuged at 700 X g for 10 mins. For membrane
isolation the supernatant fraction was further centrifuged and 16,000 X g for 12 min and
resuspended in sucrose phosphate buffer (SP) ( 0.32M sucrose).
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Analysis of DAT Palmitoylation by Acyl-Biotinyl Exchange
DAT palmitoylation was assessed by ABE using a method modified from Wan et
al. (153). LLCPK1 rDAT or N2a cells were harvested followed by centrifugation at
20,000 x g for 12 mins at 4C. Cell pellets were solubilized in lysis buffer (50 mM
HEPES, pH 7.0, 2% SDS, 1 mM EDTA) containing Mini Complete protease inhibitor
and 20 mM MMTS to block free thiols. Lysates were incubated at room temperature for
1 hour with mixing followed by acetone precipitation and resuspension in lysis buffer
containing MMTS and incubation again for 1 hour at room temperature followed by
acetone precipitation and resuspension in lysis buffer and incubated at room temperature
overnight with end-over-end rotation. Excess MMTS was removed by three sequential
acetone precipitations followed by resuspension of the precipitated proteins in 300 µl of
4SB (4% SDS, 50 mM Tris, 5 mM EDTA, pH 7.4). Each sample was divided into two
equal portions and treated for 2 hours at room temp with 50 mM Tris-HCL, pH 7.4 or 0.7
M hydroxylamine, pH 7.4 to cleave thioester linkages. Hydroxylamine was removed with
three sequential acetone precipitations followed by resuspension of pellet in 240 µl of
4SB, and diluted with 50 mM tris containing 0.4 mM sulfhydryl-reactive (N(6(biotinamido)hexyl)-3`-(2`-pyridyldithio)-pro-pionamide (HPDP) for 1 hour at room
temp. Excess HPDP was removed by three sequential acetone precipitations followed by
resuspension of pellet in 75 µl of lysis buffer without MMTS. 10 µl of the sample was
save for total DAT and the remaining 65 µl was diluted with 50 mM Tris-HCL, pH 7.4 to
contain 0.1% SDS. Samples were affinity-purified using Neutravidin resin overnight with
end-over-end rotation at 4°C. Proteins were eluted with sample buffer (60 mM Tris, pH
6.8, 20% SDS, 10% glycerol) containing 100 mM DTT and 3% β-mercaptoethanol and
42

subjected to SDS-PAGE and immunoblotting with DAT monoclonal antibody 16
(mAb16). Palmitoylated DAT protein was normalized to total DAT protein.
Analysis of DAT Palmitoylation by [3H] Metabolic labeling
LLCPK1 rDAT cells were metabolically labeled with [9,10-3H] palmitic acid (0.5
mCi/ml) for 18 hours at 37C in AMEM media. After labeling, cells were lysed in
radioimmunoprecipitation assay buffer (RIPA: 10 mM sodium phosphate, 150 mM NaCl,
2 mM EDTA, 1% Triton X-100, , 0.1% SDS, pH 7.2). Metabolically labeled samples
were normalized to equal amounts of DAT first by immunoblotting with mAb16 then
immunoprecipitated with polyclonal Ab16. Precipitated proteins were then resolved on
4-20% SDS-polyacrylamide gels with Rainbow molecular mass markers followed by
soaking gels in Fluro-Hance (Research Products International) fluorographic reagent for
30 min, dried, and exposed to pre-flashed x-ray film for 30-90 days. Band intensities
were quantified using Quantity One software (Bio-Rad), and values were normalized to
total DAT levels.
Immunoprecipitation and SDS-PAGE Western Blot
DAT immunoprecipitation and immunoblotting were performed using polyclonal
or monoclonal antibody 16 (154, 155). Samples were resolved on 4-20% SDS-PAGE
gels with Rainbow molecular mass markers then proteins were transferred to PVDF
membranes. Immunoreactive bands were visualized using Immuno-Star AP substrate and
quantified using Bio-Rad Chem Doc XRS and Quantity One 4.6.7 software.
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Surface Biotinylation
For surface biotinylation LLCPK1 or N2a cells were transiently transfected with
co-expressed rDAT and DHHC enzymes. Cells were washed three times with ice cold
Hank’s buffer salt solution (HBSS) Mg-Ca (HBSS, 1mM MgSo4, 0.1 mM CaCl2, Ph
7.4), incubated twice with 0.5mg/mL of membrane-impermeable reagent, sulfo-NHS-SSbiotin for 25 min each at 4°C. The biotinylation reagent was removed and the reaction
was quenched by two sequential incubations with 100 mM glycine in HBSS Mg-Ca for
20 min each at 4°C. Cells were then washed with HBBS Mg-Ca and lysed with RIPA
containing a Complete Mini protease inhibitor tablet/10 ml. Equal cell lystes (100 ug
protein) samples were affinity-purified using Neutravidin resin overnight with end-overend rotation at 4°C. The beads were washed three times with RIPA buffer and the bound
protein was eluted with 32 µl of sample buffer followed by immunoblotting with mAb16.
Surface localization of biotinylated DAT protein was confirmed by probing blot for
intracellular protein using anti protein-phosphatase 1 α (PP1α) antibody. For some
experiments samples were probed for anti-transferrin receptor. Surface expression was
normalized to total DAT or total transferrin receptor.
[3H] DA Uptake Assay
LLCPK1 expressing WT rDAT or N2a cells transiently transfected with WT
rDAT and DHHC enzymes were grown to 80-90% confluence. Cells were washed twice
with Krebs-Ringer HEPES (KRH) buffer (25 mM HEPES, 125 mM NaCl, 4.8 mM KCl,
1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4, 5.6 mM glucose, pH 7.4). Interval
DA uptake was initiated by adding 10 µl of a 100X DA stock solution to bring the final
concentration of [3H] DA to 10 nM and that of total DA to 3 µM. Nonspecific uptake
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was determined by addition of 100 µM (—) –cocaine. Uptake assay was performed at
37°C for 8 minutes and terminated by rapidly washing the cells two times with ice-cold
KRH buffer. Cells were solubilized in RIPA containing protease inhibitor tablet.
Radioactivity contained in lysates was measured by liquid scintillation counting. Uptake
activity was normalized to total protein as determined by BCA assay.
Subcellular localization of palmitoylated DATs
Subcellular fractions were generated by differential centrifugation LLCPK1 cells
stably expressing WT rDAT were cultured in 150 mm dishes, grown to ~90%. Cells were
washed, scraped, and pelleted by centrifugation at 700 x g for 5 min at 4 °C. Pelleted
cells were resuspended in Buffer C (0.25M sucrose, 10 mM triethanolamine, 10 mM
acetic acid, 1 mM EDTA, pH 7.8) and homogenized in ice-cold Buffer C with 30 strokes
in a Dounce homogenizer. Homogenates were centrifuged at 700 x g to remove nuclei,
and post- nuclear supernatants (totals), were centrifuged sequentially at 16,000 x g for 12
min (16,000 x g membranes), and at 200,000 x g for 1h (200,000 x g membranes).
Resulting pellets were resuspended at the original volume in RIPA buffer containing
protease inhibitors. Fractions were immunoblotted for DAT, Na+/K+ ATPase, Rab5A,
Rab7, and Rab11, or analyzed by ABE for detection of DAT palmitoylation.
Fluorescence Recovery After Photobleaching (FRAP)
FRAP studies were done with a Zeiss 510 META laser scanning confocal
microscope. N2a cells were grown to ~50% on 1 mm glass coverslips and transiently
transfected with EYFP WT rDAT and individual HA-tagged DHHC enzymes. Spot
photobleaching using circular regions of interest 30 µm in diameter were placed on the
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membrane of the visualized cell, followed by bleaching of the region using the 514 nm
laser at 100% power to obtain 50-70% bleaching. Images were at collected at 2% laser
power in 3.93 sec intervals for a duration of 5 mins totaling 100 images. The images were
processed in ImageJ and recovery curves were calculated. The rate of recovery (t ½) was
calculated from an exponential recovery function (F(x)=F”∞”+A(exp9-XT)) fitted to the
fluorescence recovery data.
In vivo Analysis of DAT Palmitoylation in Rats
Male Sprague Dawley rats (175-350g) were subcutaneously (SC) injected with
saline (control), METH (15 mg/kg), or cocaine (15 mg/kg) for 10, 30, 60 min post SC
injection. The animals were decapitated and the striata rapidly removed, weighed and
place in ice-cold 0.32 M SP buffer. Striatal tissue was homogenized with a Polytron
PT1200 homogenizer (Kinematica, Basel, Switzerland) for 8 seconds and centrifuged at
3,000 x g for 3 min at 4 ºC. The supernatant was then centrifuged at 16,000 x g for 12
min. The resulting pellet was resuspended in modified Krebs phosphate buffer (126 mM
NaCl, 4.8 mM KCl, 16 mM KPO4, 1.4 mM MgSO4, 10 mM glucose, 1.1 mM ascorbic
acid, and 1.3 mM CaCl2, pH 7.4) to 20 mg/ml original wet weight. The membranes were
then analyzed for palmitoylation by ABE as previously described.

46

CHAPTER III
RESULTS
Identification of DAT Palmitoyl Acyl Transferases
Protein palmitoylation is known to regulate many diverse aspects of neuronal
protein trafficking and function (112, 113, 120, 156), however its role in DAT function is
poorly understood. Furthermore, 23 PAT enzymes that have been identified in the human
genome (112, 125, 128–130), yet the enzymes that catalyze DAT palmitoylation still
remain unknown. Previous studies have shown that DAT is palmitoylated and that
inhibition of DAT palmitoylation affects the function of the transporter (149), therefore
identifying the enzymes that drive palmitoylation is of great interest. The mammalian
PAT enzymes have varying tissue and subcellular distribution, and a few, if any, specific
pharmacological activators or inhibitors for these enzymes, making the identification of
PATs that catalyze DAT palmitoylation difficult. To determine which PATs play a role in
DAT palmitoylation we choose a specific subset of DHHC 2, 3, 5, 7, 8, 9, 11, 15, 17, 20,
21, and 22, known to be expressed in a neuronal context or those associated with
neurological disorders. In our initial studies, we wanted to determine in a model cell
system if we could co-express the DHHC enzymes with DAT. For these studies, LLCPK1
cells expressing wild type (WT) rDAT were transiently transfected with individual HAtagged human (h) DHHC coding plasmids kindly provided by Dr. Masaki Fukata from
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Figure 9: DHHC expression in rDAT LLCPK1 cells. rDAT LLCPK1 cells were transiently
transfected with the indicated HA-tagged DHHC coding plasmids for 18 h. Cells were
immunoblotted for DAT (mAB16) and DHHC expression (anti-HA). GST tagged plasmid
was used as a transfection control. Blots are representative of three independent
experiments.

48

Figure 10: Acyl-biotinyl exchange method. The ABE method consists of three major steps:
blockade of unmodified free Cys thiols with MMTS; cleavage of palmitoylation thioester
linkages with NH2OH; and labeling of newly exposed Cys thiols with a thiol specific
biotinylation reagent. Biotinylated proteins are extracted with NeutrAvidin agarose
followed by SDS-PAGE and immunoblotting for DAT. Image modified from Yuko Fukata
and Masaki Fukata. 2010. Protein palmitoylation in neuronal development and synaptic
plasticity Nature Rev. Neuroscience 11(3): 161-175, with permission

49

Figure 11: Multiple DHHC enzymes increase DAT palmitoylation. rDAT LLCPK1 cells
transiently transfected with the indicated DHHC coding plasmids were harvested and
membranes isolated, followed by assessment of DAT palmitoylation by ABE. Upper
panels show representative ABE blots with matching total DAT immunoblots for increased
palmitoylation (A and B) and for no effect (C). Histogram represents quantification of
palmitoylated DAT normalized for total DAT protein expressed as a fraction of control
values normalized to 100% (means ± S.E. of 3-4 experiments performed in triplicate). *
p< 0.05, ** p<0.01 relative to control by (one-way ANOVA with Dunnett’s Post hoc test).
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the National Institute for Physiological Sciences, Okazaki, Aich Japan. DHHC coexpression was verified by immunoblotting cell lysates 18 h post transfection using an
anti-HA antibody (Figure 9). The DHHC enzymes and DAT were easily detectable,
indicating successful co-expression of these proteins in our mammalian cell system. The
same vector containing the coding sequences for GST was used as a transfection control
(Figure 9 far right).
To determine which PATs play a role in DAT palmitoylation, experiments were
performed by comparing DAT palmitoylation in the presence of co-transfected DHHCs.
For most experiments, DAT palmitoylation was analyzed by the in vitro acyl-biotinyl
exchange (ABE) method. In this method, samples are treated with methyl
methanethiosulfonate (MMTS) to block free thiols, followed by treatment with
hydroxylamine (NH2OH) to remove thioester-linked palmitate, with parallel samples
treated with Tris-HCl (control), and finally the newly exposed cysteine thiols were
labeled with a sulfhydryl-reactive biotin for NeutrAvidin extraction followed by SDSPAGE and immunoblotting for DAT. The method is depicted in Figure 10.
Our findings (Figure 11) show that DAT palmitoylation is enhanced relative to
control by over-expression of DHHC2 (141.6 ± 12%, p<0.001), DHHC3 (127.8 ± 7%,
p<0.01), DHHC8 (138.7 ± 12%, p<0.001), DHHC15 (132.4 ± 6%, p<0.001), and
DHHC17 (121.9 ± 4% p<0.05). Several other co-expressed DHHC enzymes (DHHC5, 7,
9, 11, 20, 21, and 22) however had no effect on DAT palmitoylation (p>0.05), indicating
a substrate specific. It is also important to note that the immature form of DAT was also
palmitoylated (not shown) in all cases. Taken together, these results indicate that multiple
DHHC enzymes may have the capability to modify DAT palmitoylation
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Figure 12: DHHC2-induced DAT palmitoylation validated by [3H]palmitic acid labeling.
rDAT LLCPK1 cells were transiently transfected with HA-tagged DHHC2 coding plasmid.
After four hours, media was removed and cells were metabolically labeled with
[3H]palmitic acid for 18 h. Cell lysates were immunoprecipitated followed by SDSPAGE/fluorography. Upper panel shows representative results for autoradiogram (top) and
western blot of total DAT (bottom). Histogram represents quantification of means ± S.E
three independent experiments performed in triplicate relative to control normalized to
100%. ** p<0.01 DHHC2 versus control (Student’s t-test).
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Figure 13: Enzymatic activity of DHHC2 is required for increased DAT palmitoylation.
ABE analysis of rDAT LLCPK1 cells transiently transfected with DHHC2 or C→A
mutation DHHA2. Upper panel shows representative results for ABE. Histogram
represents quantification of palmitoylated DAT normalized for total DAT protein
expressed as a fraction of control values normalized to 100% (means ± S.E. of four
independent experiments performed in duplicate). ** p< 0.01, *** p<0.001 relative to
control by (one-way ANOVA with Tukey’s post hoc test)
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To confirm our ABE results, we performed metabolic labeling with [3H]palmitic
acid (Figure 12). LLCPK1 cells stably expressing WT rDAT were transiently transfected
with HA-tagged DHHC2 and labeled with palmitic acid. Co-expression with DHHC2
significant increased DAT [3H] palmitoylate labeling relative to control (138 ± 11% versus
control, p <0.05). Although this method is known to be less sensitive (157), the increases
in DAT palmitoylation was similar to the results obtained by ABE. These results confirm
that DAT palmitoylation is driven by the overexpression of DHHC enzymes.
To demonstrate that acyl transferase activity in the co-expressed DHHC was
necessary for increased DAT palmitoylation, an inactive DHHA2 enzyme was utilized
(158). Site directed mutagenesis was used to converted DHHC2 to DHHA2, changing the
Cys at position 156 to an Ala, making the enzyme inactive (158). Expression levels of the
mutant DHHA2, determined by anti-HA immunoblotting was equivalent to the WT
DHHC2 (Figure 9 far right). Co-expression with WT DHHC2 significantly increased
DAT palmitoylation (p<0.001) compared to control, however DHHA2 resulted in no
change in DAT palmitoylation (DHHA2 78.8 ± 3% relative to control p>0.05), and was
significantly different from the WT DHHC2 enzyme (p<0.001) (Figure 13). These results
indicate that the enzymatic activity of DHHC2 is required for increased DAT
palmitoylation.
Palmitoylation Enhances DAT Expression
Previous studies have shown acute or chronic inhibition of palmitoylation by 2BP
results in increased DAT degradation, as detected by the loss of full-length DAT and
appearance of DAT degradation fragments (149). Therefore it was hypothesized that PAT
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Figure 14: DAT palmitoylation increases total DAT expression. rDAT LLCPK1 cells
were transiently transfected individually with HA-tagged DHHC coding plasmids for 18h
equal amounts of protein were immunoblotted for DAT. Top panel shows representative
immunoblots and histogram shows band density expressed as a fraction of control values
normalized to 100% (means ± S.E. of 4 independent experiments performed in
duplicate). * p<0.05, ** p<0.01, *** p<0.001 versus control. (one-way ANOVA with
Dunnett’s post hoc test).
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Figure 15: Functional studies in LLCPK1 cells. rDAT LLCPK1 cells were transiently
transfected with the indicated HA-tagged DHHC coding plasmids and assayed for DA
uptake activity and surface expression. (A) DA uptake activity normalized to total protein.
Histogram is presented as means ± S.E. of 3-4 independent experiments relative to control
normalized to 100% p>0.05 by ANOVA with Dunnett’s post hoc test. (B) Surface
biotinylation analysis of LLCPK1 cells co-expressing indicated DHHC enzymes.
Representative immunoblots showing equal amounts of protein analyzed for DAT total and
surface levels Histogram is presented as means ± S.E. 2 independent experiments relative
to control normalized to 100%. p>0.05 by ANOVA with Dunnett’s post hoc test.
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enzymes that drive DAT palmitoylation would also increase total DAT expression. To
test this, LLCPK1 cells stably expressing WT rDAT were transiently transfected with
individual DHHC coding plasmids for 18h, and cell lysates immunoblotted for total DAT
(Figure 14). Results show that total DAT levels were increased by co-expression of
DHHC enzymes that increase DAT palmitoylation (DHHC2 123 ± 3%, p<0.01; DHHC3
134 ± 9%, p<0.001; DHHC8 119 ± 1%, p<0.05; DHHC15 121 ± 4%, p<0.05, DHH17 ±
8%, p<0.01). The DHHC enzymes that had no effect on DAT palmitoylation did not
increase total DAT expression, (DHHC 5, 7, 9, 11, 20, 21, and 22, p>0.05). Coexpression with the inactive enzyme DHHA2, which did not increase DAT
palmitoylation, also resulted in no change in total DAT levels (100 ± 6%, p>0.05),
supporting the modification of DAT as driving this effect. Together with our previous
2BP finding, these results demonstrate that palmitoylation opposes DAT degradation.
Functional Studies of DAT Palmitoylation in LLCPK1 Cells
To further understand the role of DAT palmitoylation, we investigated the
functional effects. Previous studies demonstrated that inhibition of DAT palmitoylation
with 2BP decreased DA transport activity (149), therefore we hypothesized that increased
palmitoylation would result in increased DAT activity. To test this LLCPK1 cells stably
expressing WT rDAT were transiently transfected with indicated DHHC enzymes for 18
h, followed by assessment for [3H]DA uptake (Figure 15A). Surprisingly, we found that
DA transport activity was not altered when co-expressed with DHHC enzymes that
increased DAT palmitoylation (DHHC2 and DHDHC3 p>0.05). Because we did not seen
a change in transport activity we assessed plasma membrane levels by surface
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Figure 16: DHHC enzymes increase DAT palmitoylation in N2a cells. N2a cells transiently
transfected with WT rDAT and indicated DHHC coding plasmids were harvested and
membranes isolated, followed by assessment of DAT palmitoylation by ABE. Upper
panels show representative ABE blots and matching total immunoblots for increased
palmitoylation (A) and for no effect (B). Histogram shows quantification of palmitoylated
DAT normalized for total DAT protein expressed as a fraction of control values normalized
to 100% (mean ± S.E. of 3-5 experiments performed in duplicate). * p< 0.05, ** p<0.01
relative to control by (one-way ANOVA with Dunnett’s Post hoc test)
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biotinylation to determine if changes in surface expression were occurring (Figure 15B).
Results indicated no change in surface DAT when normalized to total DAT for all DHHC
enzymes assessed (DHHC2, 3, 8, and 11 (p.>0.05). Control experiment with AMPH
resulted in decreased surface biotinylation, indicating internalization of DAT (Figure 15B
lane 2). These results were unexpected, demonstrating increased DAT palmitoylation does
not change transport activity or surface expression. Based on previous results (149) we
predicted changes in DAT palmitoylation would be accompanied by functional changes.
Studies have suggested functional differences between neuronal and non-neuronal cells
lines (109). Therefore we decided to perform the analyses in the Neuro-2A (N2a)
neuroblastoma cell line derived from mouse to determine if a neuronal cell provided a
better model system.
Multiple PATs Enhance DAT Palmitoylation and Expression in the N2a Cells
Because we already determined a specific subset of DHHC enzymes the drive
DAT palmitoylation in the LLCPK1 cells, we chose to evaluate a limited number of
DHHC enzymes in the N2a cells, to determine if the previous results followed a similar
pattern. To test this, N2a cells were transiently transfected with WT rDAT and/or select
DHHC enzymes for 18 h and analyzed by ABE (Figure 16). In these experiments we
found significant increases in DAT palmitoylation relative to control with the overexpression of DHHC2 (147.3 ± 19%, p<0.05), DHHC3 (173.1 ± 6%, p<0.01), and
DHHC8 (145.7 ± 26%, p<0.05), whereas DHHC5 (98.1 ± 1%) and DHHA2 (97.9 ± 2%)
had no effect (p>0.05) on DAT palmitoylation, parallel to our findings the LLCPK1 cells.
Additional experiments were performed to determine if the N2a cells also showed
an increase in total DAT expression when DHHC enzymes were overexpressed. N2a
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Figure 17: DAT palmitoylation increases total DAT expression in N2a cells. N2a cells were
transiently transfected with WT rDAT and indicated HA-tagged DHHC coding plasmids
for 18 h and assessed for total DAT expression. Equal amounts of protein were
immunoblotted for DAT (representative blot shown) and band density was quantified and
expressed as a fraction of control values normalized to 100% (means ± S.E. of 2-6
independent experiments performed in duplicate). * P<0.05, ** P<0.01, *** P<0.001
versus control. (one-way ANOVA with Dunnett’s post hoc test).
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Figure 18: DAT palmitoylation increases transport Vmax in N2a cells. (A) N2a cells were
transiently transfected with WT rDAT and the indicated HA-tagged DHHC coding
plasmids followed by [3H]DA uptake. Transport values obtained with co expression of
DHHC enzymes were normalized to total protein. Values shown are mean ± S.E. of 3-5
independent experiments performed in triplicate relative to controls normalized to 100%.
*p < 0.05, ** p < 0.01 versus WT (one-way ANOVA with Dunnett’s Post hoc test). (B)
DA transport saturation analysis of N2a cells co expressed with rDAT and DHHC2. Results
shown are mean ± S.E of 3 independent experiments performed in triplicate, *p < 0.05
(Student’s t-test).
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cells were transiently transfected with WT rDAT and/or select DHHC enzymes for 18 h,
cell lysates were subjected to SDS-PAGE, and immunoblotted for total DAT levels. Our
results were similar to our previous findings, indicating that total DAT expression is
enhanced when DAT is co-expressed with DHHC enzymes that increased DAT
palmitoylation (Figure 17). DAT expression was significantly increased with the coexpression of DHHC2 (131.2 ± 7%, p<0.01); DHHC3 (138.6 ± 13%, p<0.001); DHHC8
(143.6 ± 15%, p<0.05); DHHC15 (151.5 ± 6%, p<0.05), DHH17 (139.0 ± 5%, p<0.01)
whereas DHHC11 and the inactive DHHA2 enzyme had no effect on total expression
(p>0.05). These results support our findings in the LLCPK1 cells, suggesting DAT
palmitoylation oppresses DAT degradation.
Palmitoylation Increases Transporter Capacity via an Alternation of DAT Transport
Kinetics
Previous research has shown inhibition of DAT palmitoylation with 2BP results
in a significant decrease in transport capacity (149). Therefore we wanted to investigate
the functional effects of DAT palmitoylation when driven by the overexpression of
DHHC enzymes. To do this, N2a cells were transiently transfected with WT rDAT and
individual DHHC enzymes for 18 h, then assessed for [3H]DA uptake activity (Figure
18A). We found that DA transport activity was significantly enhanced by all DHHC
enzymes that increased DAT palmitoylation (DHHC2 130 ± 9%, p<0.01; DHHC3 145 ±
8%, p<0.01; DHHC8 152 ± 21%, p<0.001; DHHC15 138 ± 5%, p<0.05; and DHHC17
136 ± 10% p<0.05) but that uptake was not changed with the co-expression of DHHC
enzymes that did not enhance DAT palmitoylation (DHHC11 107 ± 3% and DHHA2 98
± 3%, p>0.05). To determine the mechanism underlying increased uptake activity, we
performed a [3H]DA saturation analysis to determine if the kinetic properties were
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Figure 19: Palmitoylation of DAT does not increase surface expression. N2a cells were
transiently transfected with WT rDAT and the indicated HA-tagged DHHC coding
plasmids followed by surface biotinylation analysis. Image represents eluted biotinylated
fraction (upper panel) normalized to transferrin receptor (TrF) (lower panel). The
histogram represents mean ± S.E of 5-8 independent experiments relative to controls
normalized to 100%. p > 0.05 by ANOVA with Dunnett’s post hoc test.
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affected by the overexpression of DHHC2 (Figure 18B). Saturation analysis showed
DHHC2-induced increases in transport occurred via an increase in Vmax relative to
control (9.20 ± 0.75 versus 5. ± 0.73 pmol/min/mg, p<0.05), with no effect on Km (1.02 ±
.42 and 2.3 ± 1.40 nM, p>0.05). Together, these results indicate that DAT palmitoylation
affects the transport capacity of the transporter.
To investigate the mechanism of DHHC-induced DA transport increases, we
analyzed surface expression of DAT. To do this, N2a cells were transiently transfected
with WT rDAT and individually with DHHC2 and DHHA2 followed by analysis by cell
surface biotinylation (Figure 19). In five independent experiments performed in
duplicate, quantification of surface DAT normalized to the transferrin receptor for each
condition showed surface levels of DAT were not different from control levels (DHHC2
98 ± 7% DHHA2 104 ± 10% compared to control set at 100%, p>0.05), indicating that
DAT surface expression is not affected by its palmitoylation status. Together with our
[3H]DA uptake data, our results indicate that DAT palmitoylation increases transport
Vmax via an alternation of surface transport kinetic capacity.
Palmitoylation is Present on Surface Transporters
Kinetic regulation of DA transport activity by palmitoylation requires the modification to
be present on surface transporters. To examine this, rDAT LLCPK1 cells were subjected
to subcellular fractionation following analysis by ABE of DAT palmitoylation (Figure
20). Post-nuclear supernatants were subjected to differential centrifugation to generate
fractions enriched in plasma membranes (16,000 x g pellets) or endosomes (200,000 x g
pellets) (26). Immunoblotting showed enrichment of the plasma membrane marker
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Figure 20: Subcellular localization of palmitoylated DATs. rDAT LLCPK1 cells were
homogenized and post-nuclear supernatants (totals) were subjected to differential
centrifugation to produce 16,000 x g membranes and 200,000 x g membranes. Fractions
were immunoblotted for Na+-K+-ATPase, Rab5A, or DAT. Samples were subjected to
ABE for detection of DAT palmitoylation. Results are representative of 3-4 independent
experiments performed in duplicate.
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Na+/K+-ATPase in the 16,000 x g membranes and the early endosomal marker Rab5A in
the 200,000 x g membranes, confirming the separation. ABE analysis showed that
palmitoylated transporters were mostly present in the 16,000 x g membranes, with a
small amount present in the endosomal fraction. These results support the presence of
palmitoylated DATs on the plasma membrane.
DAT Palmitoylation at Cys580
We next investigated Cys580, the major site of DAT palmitoylation, and the role
this site plays in DHHC-induced DAT palmitoylation. To do this, LLCPK1 rDAT cells
stably expressing the C→A mutation at 580 were transiently transfected with DHHC2 for
18 h followed by analysis of palmitoylation by ABE (Figure 21A). In contrast to WT coexpression of DHHC2 and C580A rDAT resulted in no change in DAT palmitoylation
(DHHC2 87.7% ± 6% relative to control p>0.05). Transport activity of Cys580 and coexpression of DHHC2 were also assessed (Figure 21B). In three independent
experiments, DA transport activity was significantly increased with the co-expression of
DHHC2 in WT expressing cells (p<0.05). Whereas co-expression of DHHC2 in C580A
expressing cells resulted in no effect on DA transport activity (DHHC2/C580A relative to
control 74 ± 10% p>0.05), indicating Cy580 is required for DHHC2-induced uptake.
Taken together, these results indicate that Cys580 mediates DHHC2-induced DAT
palmitoylation and increased DA uptake activity.
Previous studies have shown that DA transport Vmax is significantly reduced by
conditions that inhibit DAT palmitoylation (149), suggesting that palmitoylation of
Cys580 increased transport. To further investigate the role of palmitoylation on transport
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Figure 21: Cys580 mediates DHHC2-induced DAT palmitoylation and effects on
kinetics. (A) C580A rDAT LLCPK1 cells transiently transfected with DHHC2 were
analyzed by ABE for DAT palmitoylation. Upper panels show representative results for
ABE. Histogram shows quantification of palmitoylated DAT normalized for total DAT
protein (means ± S.E. of 4 experiments performed in triplicate relative to controls
normalized to 100%). p>0.05, relative to control by (Student’s t test). (B) [3H]DA uptake
analysis in N2a cells transiently co-transfected with WT or C580A rDAT, and HA-tagged
DHHC2 coding plasmid. Transport activity was normalized to total protein. Values
shown are mean ± S.E. of 3-5 independent experiments relative to controls and C580A
normalized to 100%. *p < 0.05 ***p < 0.001 by ANOVA with Tukey’s post hoc test.
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Figure 22: Cys580 modulates DA transport Vmax. LLCPK1 cells expressing WT and C580A
were analyzed in parallel for [3H] DA saturation transport kinetics, total DAT expression,
and DAT cell surface expression. (A) Representative immunoblots showing equal amounts
of protein analyzed for DAT total and surface levels. (B) [3H] DA saturation analysis
normalized for relative transporter surface levels. Uptake values shown are the mean ± S.E.
of five independent experiments. (C) The histogram shows Vmax values for WT and C580A.
*, p<0.05. Statistical analyses were performed by ANOVA with a Tukey post-hoc test.
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kinetics we performed [3H]DA saturation transport analyses for C580A and WT DATs
(Figure 22). All experiments were performed in parallel and include analysis of samples
for total and surface DAT expression. Relative to the WT transporters values set at 100%,
total and surface expression of C580A rDAT was 55 ± 5% and 56 ± 4%, respectively
(Figure 22A). Figure 22B shows uptake saturation values for WT and C580A normalized
for surface expression. The Vmax of C580A (397 ± 34 pmol/min/mg) was significantly
less than the WT protein (697 ± 56 pmol/min/mg; p<0.05) (Figure 22C). Km values were
not significantly different (WT 2.3 ± 0.8 µM, C580A 1.5 ± 0.6 µM; p>0.05). Similar total
and surface expression levels of C580 DAT indicate alterations in transport are not due to
differences in trafficking to the surface.
Lateral Membrane Mobility of DAT
We next wanted to investigate the lateral membrane mobility of DAT to better
understand the function of DAT palmitoylation. To do this we co-expressed EYFP-DAT
and select DHHC enzymes transiently in the N2a cells and analyzed lateral membrane
mobility using FRAP (Figure 23). We assayed the lateral mobility of DAT using a
circular bleach spot with the average diameter of 3 µm. The bleaching was performed at
the edge of the membrane, photobleaching approximately 50-70% of the fluorescence
signal. Representative images are shown in Figure 23A for DAT and DAT co-expressed
with DHHC2. The circles highlight the region of photobleaching and the subsequently
recovery recorded over a 5 min period. Our results show, that co-expression with
DHHC2, significantly increases the time of recovery as demonstrated by the recovery
curves and the histogram (Figure 23B and C) (DHHC2 107.3 ± 17 sec vs control 30.4 ± 6
sec, p<0.001). In contrast, co-expression with DHHC11 and DHHA2 resulted in
69

Figure 23: Palmitoylation decreases membrane lateral mobility of DAT. N2a cells
transiently transfected with EYFP-rDAT and indicated HA-tagged DHHC coding plasmids
were assessed for lateral membrane mobility by FRAP. (A) Representative confocal
images showing EYFP-DAT fluorescence concentrated on the plasma membrane at prebleach, bleached, and recovery stages. (B) Fluorescence recovery curves for EYFP DAT
expressed in N2a cells. Recovery was measure by normalized fluorescence intensity as a
function of time (sec). (C) Time of recovery calculated based on FRAP experiments (means
± S.E. of 3-5 independent experiments relative to controls) Total number of cells evaluated
- control: 35, DHHC2: 25, DHHC11: 28 and DHHA2: 20. **p < 0.01, *** p < 0.001 versus
control (one-way ANOVA with Dunnett’s Post hoc test).
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recovery times similar to control (DHHC11 43.0 ± 5 sec and DHHA 40.6 ± 5 sec,
p>0.05) (Figure 23B and C). Together these results indicated DAT palmitoylation
decreases the lateral membrane mobility.
Action of Psychostimulants on DAT palmitoylation
DAT is the target for power addictive psychostimulants, therefore we wanted to
investigate the effects of psychostimulants on DAT palmitoylation. To examine DAT
palmitoylation, cells were pretreated with COC or METH for 30 min, washed extensively
to remove extracellular drug, and assayed for DAT palmitoylation by ABE (Figure 24A).
In three independent experiments, COC treatment resulted in no change in palmitoylation
compared with untreated controls (94.8 ± 6%, p>0.05), whereas treatment with METH
significantly reduced DAT palmitoylation (84.2 ± 4%, p<0.05). Time course studies
showed decreased DAT palmitoylation at 30 min (83.3 ± 8%, p<0.05) and 60 min (82.1 ±
4%, p<0.05) relative to basal (Figure 24B).
To further examine the effect of psychostimulants on DAT palmitoylation, in vivo
METH studies were performed in male Sprague Dawley rats (Figure 25A). In these
studies, the animals were subcutaneously (SC) injected with COC (15mg/kg), METH
(15mg/kg) or saline control for 30 min. This dose of drug produces detectable locomotor
activity (159). Animals were then decapitated, the striatum was isolated, and membranes
were prepared, followed by analysis by ABE. In three independent experiments, COC
treatment showed no change in DAT palmitoylation compared with saline controls (94.8
± 6%, p>0.05) whereas METH treatment significantly reduced DAT palmitoylation
(p<0.05). Time course studies animals were treated with METH (15mg/kg) for 10 min,
30 min, and 60 min post SC injection (Figure 25B). We observed treatment with METH
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significantly decreased DAT palmitoylation in as little as 10 min (66.8 ± 10%, p<0.01,),
and continued for 30 min (50.8 ± 1%, p<0.001), and 60 min (47.9 ± 0.3%, p<0.01). These
results are consistent with our previous results which indicated a differential response of
psychostimulant substrates versus blockers in both heterologous cells and animals (75,
152). Furthermore, these results indicate DAT palmitoylation is regulated by METH and
not COC, which might be important for the clearance of DA in the synapse.
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Figure 24: Regulation of DAT palmitoylation by psychostimulants in heterologous cells.
LLCPK1 cells were treated with (A) 10 µM METH or 100 µM cocaine for 30 min at 37 ºC
followed by assessment by ABE. Histogram represents quantification of palmitoylated
DAT normalized for total DAT protein expressed as a fraction of basal values normalized
to 100% (means ± S.E. of 4 experiments performed in duplicate). * P< 0.05, relative to
control by (one-way ANOVA with Dunnett’s Post hoc test).(B)10 µM methamphetamine
(METH) for 30 or 60 min at 37 ºC, cell membranes made, followed by assessment of DAT
palmitoylation by ABE. Upper panels show representative ABE blots with matching total
DAT immunoblots. Histogram represents quantification of palmitoylated DAT normalized
for total DAT protein expressed as a fraction of basal values normalized to 100% (means
± S.E. of 7 experiments performed in duplicate). * P< 0.05, relative to control by (one-way
ANOVA with Dunnett’s Post hoc test).
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Figure 25: Regulation of DAT palmitoylation by psychostimulants in vivo. Male Sprague
Dawley rats were SC injected with (A) METH (15 mg/kg), cocaine (COC) (15 mg/kg), or
saline control for 30 min. The animals were decapitated and striatal membranes were made
following analysis for DAT palmitoylation by ABE. Upper panels show representative
ABE blots with matching total DAT immunoblots. Histogram represents quantification of
palmitoylated DAT normalized for total DAT protein expressed as a fraction of saline
control values normalized to 100% (means ± S.E. of 3 experiments performed in triplicate).
* p<0.05 (one-way ANOVA with Dunnett’s Post hoc test). (B) METH (15 mg/kg) or saline
control for indicated time points. The animals were decapitated and striatal membranes
were made following analysis for DAT palmitoylation by ABE. Upper panels show
representative ABE blots with matching total DAT immunoblots. Histogram represents
quantification of palmitoylated DAT normalized for total DAT protein expressed as a
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Figure 25 continued: fraction of saline control values normalized to 100% (means ± S.E.
of 2-3 experiments performed in triplicate). ** p<0.01, *** p<0.001 (one-way ANOVA
with Tukey’s post hoc test)
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CHAPTER IV
DISCUSSION
Regulation of DAT Palmitoylation by DHHC Enzymes
Complex control of DAT is exerted by various regulatory processes, including
palmitoylation. Protein palmitoylation increases protein hydrophobicity; mediates
protein-lipid bilayers interactions; and can alter protein sorting, function, and regulation
(112–116), however its role in DAT function is poorly understood. In this study, we have
demonstrated for the first time that multiple DHHC enzymes drive DAT palmitoylation
altering the function of the transporter. Figure 26 summarizes the numerous finding from
my dissertation work and previous studies supporting DAT palmitoylation. In this model
DAT palmitoylation is driven by a specific subset of DHHC enzymes resulting in
enhanced DAT palmitoylation. Our findings reveal a connection between the increased
DAT palmitoylation and total DAT expression. In all cases we observed enhanced total
DAT expression when DAT palmitoylation was increased with the co-expression of
DHHC enzymes, supporting an additional role for palmitoylation in opposing DAT
degradation. We also found DAT palmitoylation increases transporter capacity with no
change in surface expression, indicating changes in transport Vmax occur via a kinetic
mechanism. With respect to membrane lateral mobility, we found DAT palmitoylation
increases the time of recovery, suggesting palmitoylation decreases the membrane lateral
mobility of DAT. Additionally, in this study we provide evidence showing DAT
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Figure 26: Mechanism of DAT palmitoylation. A Schematic representation of DAT
palmitoylation and depalmitoylation cycles. The red palmitate group represents a known
site of palmitoylation on the C-terminus near the TM12/cytoplasm interface. Increased
DAT palmitoylation catalyzed by select DHHC enzymes results in increased total DAT
expression, increased DA transport capacity, and decreased lateral membrane mobility. In
contrast depalmitoylation by PPT enzymes results in decreased palmitoylation, decreased
transporter expression, decreased DA uptake capacity, and increase in lateral membrane
mobility. Methamphetamine (METH), C580A mutant, and 2-bromopalmitate (2BP) all
reduce DAT palmitoylation.
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palmitoylation is regulated by METH in both native and model systems. Together these
findings indicate that palmitoylation of DAT alters the function and regulation of the
transporter.
Our studies revealed that DAT palmitoylation can be catalyzed by several but not
all, DHHC enzymes evaluated, suggesting a level of substrate specificity in both the
LLCPK1 and N2a cells. Similar findings have been reported for other neuronal proteins
(112, 125, 160, 161), suggesting that substrate palmitoylation by multiple DHHC
enzymes is important for the mechanism of palmitoylation. The 23 DHHC enzymes are
found present in many intracellular localizations including the Golgi apparatus, ER, and
plasma membrane (133, 156), however it remains unknown where DAT is being
palmitoylated at. From our results we can infer DAT is being palmitoylated in some
degree in the Golgi since the immature form of DAT is palmitoylated; however, the
multiple DHHC enzymes involved in DAT palmitoylation could suggest palmitoylation
is taking place at multiple locations including the plasma membrane. The redundancy in
substrate recognition might be important for the turnover of the protein, however remains
unknown. The dynamic nature of palmitoylation and depalmitoylation could potentially
allow for multiple palmitoylation/ depalmitoylation cycles to occur during the time DAT
in synthesized to the time it is degraded. This process could require multiple DHHC
enzymes to palmitoylate DAT at different subcellular locations effecting the overall
function of the transporter.
Further support for substrate specificity was validated by [3H]palmitate labeling
and mutagenic studies, confirming DHHC2 significantly increases DAT palmitoylation.
Our studies reveled that the enzymatic activity of DHHC2 is required for increased DAT
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palmitoylation. Similar mutagenic studies have been reported (125, 130), supporting the
idea that the intact DHHC motif is required for palmitoylation (138, 162). Studies have
shown mutations of the Cys in the DHHC motif blocks both autoacylation and transfer
activity of DHHC enzymes (126), however the exact Cys was unknown. Recently, it was
discovered that the Cys of the DHHC motif is specifically required for the two step
catalytic mechanisms of palmitoylation (140). Furthermore, the same study found
mutation of the highly conserved cysteine rich domain outside of the DHHC motif also
results in activity deficits (140), suggesting the importance of this region.
Palmitoylation can alter membrane proteins in various ways, affecting the
conformation and regulation (117–121). Therefore we investigated the functional effects
of DAT palmitoylation. We found DAT palmitoylation significantly increased DA
transport with no changes in surface expression, suggesting changes in DA transport are
occurring via a kinetic mechanisms. Several observations support the occurrence of this
type of transport. Down-regulation has been shown to still occur when ConA treatment is
used to block PMA-induced DAT endocytosis (108). Furthermore, rat striatal
synaptosomes prepared in hypertonic sucrose, which is known to inhibit clathrinmediated endocytosis (163), still resulted in down regulation when treated with PMA and
2BP with surface levels unchanged (149). Our results further provide support that DA
transport can undergo regulation at the plasma membrane via a kinetic mechanism.
The mechanism for transport regulation by palmitoylation remains unknown,
however it is most likely an indirect effect that is presumably affecting the rate of
transport. Palmitoylation has been shown to affect many aspects of membrane proteins
that could attribute to changes in transporter function (117–121). Specifically,
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palmitoylation can affect the conformation of TMD (119, 164). Palmitoylation has been
shown to facilities the re-orientation of TMDs, by maximizing hydrophobic matching and
tilting a TMD peptide (117, 165). Evidence for this was provided by structural studies in
artificial lipid membranes, which the addition of a palmitoylation chain induced the tilt of
the helix in the membrane plane (165). More recently in vivo studies have suggested that
this action also occurs in full-length proteins in biological membranes (117). These
studies suggest the possibly that titling of TMD12 of DAT could affect the function of
transporter, altering the transport mechanism. The substrate translocation pathways of
DAT is formed by TMD1, TMD3, TMD6, and TMD8, (44, 55), while the major site of
palmitoylation is found on TMD12, outside the inner core and does not contribute
directly to the substrate active site. Substrate translocation occurs via an alternating
access mechanism. DAT cycles through outward and inward facing conformations that
allow for binding of substrates and release into the cytoplasm (21, 54). These
conformations are controlled by extracellular and intracellular gates residues and the
equilibrium between these conformations determines the rate of forward transport
therefore a slight tilt of the TMD 12 could have major effects on transport activity. The
dDAT structure revealed a latch-like C-terminal helix (Figure 27) thought to be important
for interactions with the cytoplasmic face of the transporter. The C-terminal helix was
found to interact with IL1 (Figure 27B), which interacts with TMD1a. The close
proximal interaction with the cytoplasmic gate suggests the C-terminal helix may be
important for activity and changes in palmitoylation could modulating transport (50).
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Figure 27. C-terminal latch of the dopamine transporter. A. x-ray crystal structure of the
Drosophila melanogaster dopamine transporter (dDAT). (A). Locations of the open
extracellular gate (red box), closed intracellular gate (blue box), and C-terminal latch
(green box). (B). The C-terminal helix following TMD12 is bound to the cytoplasmic
face of the transporter via ionic interactions with IL1. Polar and electrostatic bonds are
represented by gray dashed lines. Image modified from A. Penmastal, K.H. Wang, and E.
Gouaux. 2013. X-ray structure of the dopamine transporter in complex with tricyclic
antidepressant. Nature 503(7474): 85-90, with permission
.
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Palmitoylation can also alter protein-protein interactions (164). Alternations in
protein interactions is thought to occur through either by steric hindrance, changes in
conformation, and/or localization to the membrane interface (164). Palmitoylation has
been shown to affect interactions of proteins in both positive and negative ways (119,
164). Studies by McCormick et al. found palmitoylation is requires for the interaction of
the mannose-6-phosphate receptor and a larger multiprotein complex important for
lysosomal targeting (166), however others have shown palmitoylation hinders proteinprotein interactions (117, 167). DAT interacts with numerous proteins on both the N-andC-termini (77, 79, 86–91, 94) that affect the overall function of the transporter. Proteins
like Rin, CaMKII, α-Syn, Park, and PICK1 all bind all on the C-terminus of DAT (79)
and it is unknown if palmitoylation affects the interactions. Furthermore, the important
FREKLAYA (residues 587-596) endocytic regulatory domain important for both basal
and PKC-enhanced DAT internalization (87) is also near the C-terminus palmitoylation
site. At this point it is unknown if DAT palmitoylation affects these important binding
partners. It will be important in the future to determine if these interaction are effected in
a positive or negative manner and if they are important for regulation of DAT.
Additional validation studies were done to evaluate our palmitoylation deficient
mutant, C580A for palmitoylation and activity when co-expressed with DHHC2. In these
studies, we found DAT palmitoylation and transport activity was not increased when
palmitoylation was driven by DHHC2, suggesting Cys580 mediates DHHC2-induced
changes in DAT palmitoylation. As previously mentioned palmitoylation can alter
protein-protein interactions a (112–115), affecting the function of other proteins.
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Figure 28. Proposed mechanism of increased DAT expression by DHHC enzymes.
Schematic representation of DAT palmitoylation, showing populations possessing
decreased

palmitoylation

(left)

or

increased

palmitoylation

(right).

Increased

palmitoylation is driven by the overexpression of PAT enzymes, whereas depalmitoylation
is catalyzed by PPT enzymes. Conditions that increase palmitoylation and total DAT
expression are predicted to retain DAT in endosomes resulting in reduced lysosomal
degradation. In contrast, decreased palmitoylation and total DAT expression is predicted
to have reduced DATs in endosomes with increased lysosomal degradation
.
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However, our results indicate DHHC2 is increasing DAT palmitoylation and transport
activity, by palmitoylating the transporter directly at Cys580.
To further support increased DAT palmitoylation effects transporter function, we
investigated total DAT expression. Our studies revealed that increased DAT palmitoylation
results in increased total DAT expression, suggesting palmitoylation opposes DAT
degradation. These results are consistent with our previous studies, which have shown that
acute or chronic inhibition of palmitoylation by 2BP results in increased DAT degradation
as detected by loss of full-length DAT and the appearance of DAT degradation fragments
(149). We know that increased DAT expression is not found at the surface as demonstrated
by the surface biotinylation experiments, suggesting increased expression is the result of
decreased DAT degradation (Figure 28). We suggest that increased palmitoylation
stabilizes DAT in the endosome and reduces DAT targeting to the lysosome, resulting in
higher expression and reduced degradation. A small amount of palmitoylated DAT was
found in the 200,000 x g fraction of the subcellular fractionation, indicating DAT is in fact
in the endosomes. Multiple studies have shown that palmitoylation is important for
regulating protein turnover (127). Increased protein turnover and reduced stability has also
been found for palmitoylation defective mutants of multiple proteins including, vial
membrane glycoprotein of Rous sarcoma virus, the Al adenosine receptor, and the
chemokine receptor CCR5 (168–170). Furthermore, we found C580A DAT has a higher
rate of turnover compared to the WT protein, suggesting palmitoylation stabilizes DAT
(Amy Mortiz, University of North Dakota, personal communication). Our results provide
additional support that palmitoylation opposes DAT degradation.
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Palmitoylation has also been shown to alter protein function by targeting
palmitoylated proteins to lipid microdomains (164). It has been proposed that increased
palmitoylation enhances the affinity of proteins for cholesterol-rich microdomains (164,
171). The affinity of a protein for a lipid microdomain is dependent on multiple factors
including: the amino acid composition of the TMD, the interaction of multiple TMD in
homo-or hetero-multimers forms, and the interaction with protein binding partners that
also have strong associates with lipids (164). Furthermore, it has been shown that
disruption of cholesterol in microdomains with mβCD results in a significantly faster
lateral diffusion of DAT in the plasma membrane (109). In addition, control experiments
were performed in our lab in which the C580A palmitoylation deficient mutant and
treatment with 2BP both resulted in decreased lateral membrane mobility (Madhur
Shetty, University of North Dakota, personal communication). From our studies we
speculate palmitoylation could be reducing the membrane lateral mobility of DAT in
various ways. The obvious mechanism is palmitoylated DAT is targeted to lipid
microdomains, thus reducing lateral membrane mobility and affecting the function of the
transporter. However, recent data from our lab suggests reduced palmitoylation actually
targets DAT to rafts domains (Madhur Shetty, University of North Dakota, personal
communication), suggesting increased palmitoylation does not target DAT to lipid
membrane rafts. Another mechanism which might result in reduced lateral mobility of
DAT is protein-protein interactions. It is well known that DAT has multiple binding
partners that affect its function (79) as previously mentioned. Furthermore,
palmitoylation can promote protein-protein interactions by modifying the conformation
of the protein (164). Therefore enhanced DAT palmitoylation could promote interactions

85

with known DAT binding partners, resulting in reduced lateral membrane mobility. DAT
palmitoylation could also be promoting DAT oligomerization, again reducing lateral
membrane mobility
In this study we provided the first evidence that DAT palmitoylation is regulated
by METH. We found treatment with METH for 30 and 60 min in LLCPK1 cells resulted
in a significant decrease in DAT palmitoylation. In addition, animals SC injected with
METH for 10, 30, and 60 min were also found to have decreased DAT palmitoylation,
demonstrating an important similarity between native and model systems. Interestingly,
cocaine treatment had no effect on DAT palmitoylation, suggesting a difference in
regulation between the two drugs. Similar studies have been done; however,
phosphorylation was measured after METH treatment (39). In these studies, Cervinski et.
al. found treatment with AMPH or METH resulted in a significant increase in DAT
phosphorylation. The DAT blocker cocaine, however did not affect DAT phosphorylation
but prevent the phosphorylation increase induced by METH (39). Together, these studies
suggest palmitoylation and phosphorylation may be working opposite of each other in an
unknown mechanism.
Several observation support the occurrence of reciprocal regulation of DAT
palmitoylation and phosphorylation after METH treatment. Most recently, our lab has
demonstrated that the palmitoylation deficient mutant, C580A had enhanced basal DAT
phosphorylation levels in comparison to WT (150). In reverse experiments, the
phosphorylation mutant, S7A had increased DAT palmitoylation when assessed by [3H]
palmitate labeling. Further pharmacological experiments were done and confirmed the
mutagenic results. Additionally, regulation of DAT palmitoylation by DHHC enzymes
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supports the reciprocity between DAT palmitoylation and phosphorylation. Studies have
shown, treatment with METH, which increases DAT phosphorylation (39), results in
DAT downregulation and endocytosis (39, 71–73). In contrast, our studies demonstrate
enhanced palmitoylation by the over expression of DHHC enzymes drive DAT
palmitoylation, resulting in increased DA transport capacity. Together these studies
provide further evidence that palmitoylation and phosphorylation are reciprocally
regulated and important for DAT regulation and function
Similar mechanisms have been shown for other proteins as well (121, 172–174).
Examples of this include the β2-adrenergic receptor in which palmitoylation of Cys341
interferes with PKC-mediated phosphorylation of Ser345 and Ser346, modulating the
capacity which the receptors interacts with Gs (172). Another example is
phosphodiesterase 10A, in which phosphorylation of Thr16 regulates trafficking and
localization by preventing palmitoylation of Cys11 (121). Although similar in
mechanism, these examples are different from DAT because the phosphorylation and
palmitoylation sites of β2-adrenergic receptor and phosphodiesterase 10A are in close
proximity in the primary sequence, while DAT’s sites are far apart in the primary
sequences. This could suggest that the N-and-C termini are in close proximity in the
tertiary structure, however based on the current crystal structures, (44, 52) little is known
about the N and C termini interactions.
Disruption in dopaminergic signaling is thought to be the consequence of
dysregulation of DAT resulting in abnormal DA clearance (175). Studies have shown
non-coding single nucleotide polymorphisms and variable-number tandem repeats in the
DAT1 gene to correlate with predisposition to various neurological and psychiatric
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disorders (176). More recently, rare coding polymorphisms have been identified in
patients diagnosed with ADHD ,bipolar disorder, and autism spectrum disorder (68, 177–
180). These mutations have been shown to affect DAT function in numerous way
including elevated efflux and increased transporter phosphorylation (178–180).
Likewise, we know from numerous studies that DHHC enzymes have been associated
with dopaminergic and neuropsychiatric diseases such as schizophrenia, X-linked
intellectual disability, Alzheimer disease, and Huntington disease (113, 141, 142, 146,
147, 181, 182), highlighting the importance of this modification in proper neuronal
function. Mutations in enzymes regulating palmitate removal can also result in disease
(147, 148), indicating that palmitoylation is relevant to disease processes. Imbalances in
DA in dopaminergic diseases may result from alterations in palmitoylation, therefore,
DHHC enzymes that catalyze DAT palmitoylation could represent potential therapeutic
targets for dopaminergic disorders and drug addiction. Overall, these results suggest that
palmitoylation plays a critical role in promoting both short-and long-term regulation of
DAT by controlling important functions of the transporter, thereby potentially impacting
neurotransmitter clearance in dopaminergic disorders.

88

APPENDIX
ABE analysis in the LLCPK1 cells

Figure 29: ABE analysis of increased DAT palmitoylation in the LLCPK 1 cells. rDAT
LLCPK1 cells transiently transfected with the indicated DHHC coding plasmids were
harvested and membranes isolated, followed by assessment of DAT palmitoylation by
ABE. Upper panels show representative ABE blots with matching total DAT immunoblots.
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Figure 30: ABE analysis of co-expressed DHHC enzymes that have no effect on DAT
palmitoylation in the LLCPK1 cells. rDAT LLCPK1 cells transiently transfected with the
indicated DHHC coding plasmids were harvested and membranes isolated, followed by
assessment of DAT palmitoylation by ABE. Upper panels show representative ABE blots
with matching total DAT immunoblots.
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ABE analysis in the N2a cells

Figure 31: ABE analysis in the N2a cells. N2a- cells transiently transfected with the
indicated DHHC coding plasmids were harvested and membranes isolated, followed by
assessment of DAT palmitoylation by ABE. Upper panels show representative ABE blots
with matching total DAT immunoblots.
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